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Summary 
A precious treasure in traditional Chinese medicine (TCM), acupuncture played a vital 
and irreplaceable role in contributing to people’s health in the thousands of years of 
Chinese history, and in 2010 was officially added to the “Representative List of the 
Intangible Cultural Heritage of Humanity” by the United Nations. Because of the 
side-effects of long-term drug therapy for pain, and the risks of dependency, 
acupuncture has been widely accepted as one of the most important alternative choice 
therapies for treating varieties of acute and chronic pain-related disorders. The clinical 
application and scientific mechanism research of acupuncture have therefore increased 
intensively in the last few decades. Besides hand acupuncture, other treatment 
approaches e.g. electroacupuncture (EA) have been widely accepted and applied as an 
important acupuncture-related technique for acupuncture analgesia (AA) research. The 
involvement of opioid peptides and receptors in acute AA has been shown via pre-EA 
application of opioid receptor/peptide antagonists. However, existing publications still 
cannot illuminate the answer to the following question: how does sustained 
antinociception happen by EA treatment? The hypothesis of opioid peptide-mediated 
tonic AA might be able to answer the question. 
 
In the first part of this thesis, the institution of a reproducible acupuncture treatment 
model as well as the endogenous opioid-related mechanisms was demonstrated. An 
anatomically-based three-dimensional (3D) rat model was established to exhibit a 
digital true-to-life organism, accurate acupoint position and EA treatment protocol on 
bilateral acupoint GB-30 Huantiao. The optimal EA treatment protocol (100 Hz, 2-3 
mA, 0.1 ms, 20 min) at 0 and 24 h after induction of inflammatory pain by complete 
Freund’s adjuvant (CFA) on conscious free-moving rats was then established. EA 
elicited significant sustained mechanical and thermal antinociception up to 144 h. 
Post-EA application of opioid receptors (mu opioid receptor, MOR; delta opioid 
receptor, DOR) antagonists naloxone (NLX) and naltrindole (NTI), or opioid peptide 
antibodies anti-beta-endorphin (anti-END), met-enkephalin (anti-ENK) or -dynorphin 
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A (anti-DYN) could also block this effect at a late phase (96 h) of CFA post-EA, which 
suggested opioid-dependent tonic analgesia was produced by EA. Meanwhile, EA also 
reduced paw temperature and volume at 72-144 h post CFA indicating 
anti-inflammatory effects. Nociceptive thresholds were assessed by paw pressure 
threshold (Randall-Sellito) or paw withdrawal latency (Hargreaves) and an 
anti-inflammatory effect was evaluated by measurement of plantar temperature and 
volume of inflamed paw. 
 
The second part of the thesis further suggests the correlation between the chemokine 
CXCL10 (= interferon-gamma inducible protein 10, IP-10) and opioid peptides in 
EA-induced antinociception. Based on a comprehensive Cytokine Array of 29 
cytokines, targeted cytokines interleukin (IL)-1alpha, interleukin (IL)-1beta, tumor 
necrosis factor (TNF)-alpha, interleukin (IL)-4, interleukin (IL)-13, interferon 
(IFN)-gamma as well as CXCL10 were selected and quantified by enzyme-linked 
immunosorbent assay (ELISA), and real time reverse transcription-polymerase chain 
reaction (RT-PCR) quantification confirmed upregulation of CXCL10 mRNA at both 
72 and 96 h. The following hyperalgesic assessment suggested the antinociceptive 
effect of CXCL10. The double immunostaining localizing opioid peptides with 
macrophages expressed the evident upregulation of CXCR3-receptor of CXCL10 in 
EA treated samples as well as the significant upregulation or downregulation of 
opioid peptides by repeated treatment of CXCL10 or antibody of CXCL10 via 
behavioral tests and immune staining. Subsequent immunoblotting measurements 
showed non-alteration of opioid receptor level by EA, indicating that the opioid 
receptors did not apparently contribute to AA in the present studies. In vitro, CXCL10 
did not directly trigger opioid peptide END release from freshly isolated rat 
macrophages. This might implicate an indirect property of CXCL10 in vitro 
stimulating the opioid peptide-containing macrophages by requiring additional 
mediators in inflammatory tissue. 
 
In summary, this project intended to explore the peripheral opioid-dependent 
analgesic mechanisms of acupuncture with a novel 3D treatment rat model and put 
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forward new information to support the pivot role of chemokine CXCL10 in 
mediating EA-induced tonic antinociception via peripheral opioid peptides. 
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Zusammenfassung 
Als wertvoller Schatz in der traditionellen chinesischen Medizin (TCM) spielt die 
Akupunktur eine wichtige und unersetzliche Rolle für die Gesundheit der Menschen in 
der über tausendjährigen Geschichte von China und wurde im Jahr 2010 offiziell in das 
"Weltkulturerbe" der Vereinten Nationen aufgenommen. Aufgrund der 
Nebenwirkungen von Langzeittherapien zur Schmerzbehandlung und dem Risiko der 
Abhängigkeit wird Akupunktur weithin als eine wichtigste Alternative für die 
Behandlung von akuten und chronischen Schmerzen eingesetzt. Die klinische 
Anwendung und Forschung in der Akupunktur wurden in den letzten Jahrzehnten 
intensiv vorangetrieben. Neben Handakupunktur gibt es noch andere 
Behandlungsmöglichkeiten, wie z.B. die Elektroakupunktur (EA). EA ist vor allem 
eine allgemein akzeptierte und wichtige akupunkturbezogene Technik für die 
Akupunkturanalgesie (AA) in der Forschung. Die Beteiligung von Opioidpeptiden und 
Opioidrezeptoren in der akuten AA wurde mittels Anwendung von 
Opioidrezeptorantagonisten/Opioidpeptidantikörpern appliziert vor EA gezeigt. Nach 
dem aktuellen Forschungsstand kann man jedoch nicht die Frage beantworten, wie die 
längerfristige (tonische) Antinozizeption nach EA-Behandlung funktioniert. Mit einer 
Hypothese zur Opioidpeptid vermittelten tonischen AA könnte man die Frage hierzu 
beantworten. 
 
In der vorliegenden Arbeit wurden in einem Modell der Akupunktur zum ersten Mal 
endogene Opioid-vermittelte Mechanismen reproduzierbar nachgewiesen. Es wurde 
ein dreidimensionales (3D) anatomisch-basiertes Rattenmodell entworfen, um am 
wachen Tier ein genaue Akupunkturbehandlung (EA) an den Akupunkten GB-30 
Huantiao beidseitig durchzuführen. Darüber hinaus wurde ein optimiertes 
Behandlungsprotokoll von EA (100 Hz, 2-3 mA, 0.1 ms, 20 min) bei Ratten 0 und 24 h 
nach intraplantarer Injektion von komplettem Freunds Adjuvans (CFA) etabliert. 
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Nozizeptive Schwellen wurden mittels Pfotendruckschwelle (Randall-Sellito) oder 
Pfotenrückzugslatenzzeit (Hargreaves) gemessen und die entzündungshemmende 
Wirkung durch Messung der Pfotentemperatur und Volumen der entzündeten Pfote 
ausgewertet. EA bewirkte eine signifikante mechanische und thermische 
Antinozizeption, welche bis zu 144 h anhielt. Die antinozizeptive Wirkung durch EA 
war nach Injektion von Opioidrezeptorantagonisten (mu opioid receptor, MOR; delta 
opioid receptor, DOR) Naloxon (NLX) und Naltrindol (NTI) oder Antikörpern gegen 
die Opioidpeptide beta-Endorphin (anti-END), Met-Enkephalin (anti-ENK) oder 
Dynorphin A (anti-DYN) während der späten Entzündungsphase (96 h) mit CFA 
blockierbar. Dies lässt auf eine durch EA induzierte tonische Analgesie schließen. 
Darüber hinaus reduzierte EA auch die erhöhte Pfotentemperatur und das erhöhte 
Pfotenvolumen, welche sehr typisch ist für eine 96-144 h Entzündung mit CFA. Dies 
spricht für eine entzündungshemmende Wirkung von EA. 
 
Nachfolgend wurde die Beteiligung von Opioidpeptiden und dem Chemokin CXCL10 
(= Interferon-gamma induziertes Protein 10, IP-10) sowie die Korrelationen zwischen 
beiden geklärt. Basierend auf umfangreichenden Zytokinarrays mit 29 Zytokinen, 
wurden die Zytokine Interleukin (IL)-1alpha, Interleukin (IL)-1beta, 
Tumornekrosefaktor (TNF)-alpha, Interleukin (IL)-4, Interleukin (IL)-13, Interferon 
(IFN)-gamma und CXCL10 gezielt ausgewählt und im Enzym Immunoassay (ELISA) 
sowie durch eine Echtzeit Reverse Transkription-Polymerase Kettenreaktion (RT-PCR) 
quantifiziert. Die Quantifizierung auf mRNA-Ebene zeigte eine Hochregulation von 
CXCL10 bei 96 h und zum früheren Zeitpunkt von 72 h. Nachfolgende 
Schmerzschwellenmessungen wiesen auf eine antinozizeptive Wirkung von CXCL10 
hin. Eine Doppelimmunfärbung zeigte die Lokalisation von Opioidpeptiden in 
Makrophagen. Nachweislich wurde die Expression des CXCR3-Rezeptor von 
CXCL10 in EA behandelten Pfoten erhöht. Ebenso kam es zu einer signifikanten 
Hochregulation von Opioidpeptiden durch wiederholte Behandlung mit CXCL10 bzw. 
Herunterregulation der Opioidpeptide nach wiederholter Behandlung mit 
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anti-CXCL10 Antikörper. Dies wurde sowohl in Verhaltenstests als auch in der 
Immunfärbung zu beobachtet. Immunoblotting zeigte keine Veränderung der 
Expression von Opioidrezeptoren nach EA, was schließen lässt, dass die Menge an 
Opioidrezeptoren in den vorliegenden Untersuchungen keine Rolle spielen. Da 
CXCL10 in vitro keine direkten Effekt auf die Freisetzung des Opioidpeptides 
beta-END aus frisch isolierten Rattenmakrophagen hat, liegt die Vermutung nahe, dass 
CXCL10 in vitro eine indirekte Rolle als Mediator zukommt und indirekt die 
Opioidpeptidfreisetzung aus Makrophagen in entzündlichen Gewebe stimuliert wird. 
 
Zusammenfassend wurden in dem hier vorgestellten Projekt die 
Opioidpeptid-abhängigen analgetischen und peripheren Mechanismen der Akupunktur 
mit einem neuartigem 3D-Behandlungsmodell der Ratte untersucht und eine 
Schlüsselrolle des Chemokins CXCL10 bei der Vermittlung der EA-induzierten 
tonischen Antinozizeption in Abhändigkeit von peripheren Opioidpeptiden. 
(Translated by Dr. Dagmar Hackel and revised by Priv.-Doz. Dr. Heike Rittner) 
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1. Introduction 
1.1 Opioid-dependent acupuncture analgesia (AA) 
Acupuncture, a traditional Chinese medicine (TCM)-related therapy, is broadly 
accepted as an important alternative medical therapy for treating varieties of acute and 
chronic pain-related disorders. Clinical application and scientific mechanism research 
of acupuncture has intensively increased in the last few decades by means of 
acupuncture-related techniques, especially electroacupuncture (EA) as one of the main 
substitutes for manual acupuncture. A great quantity studies employed EA to explore 
the mechanisms underlying acupuncture analgesia (AA). According to TCM theory, 
the fundamental basis of acupuncture treatment is considered as the regulation and 
balance of Yin and Yang [1], in contrast, scientific research in the past few decades 
discovered multiple molecular signaling pathways involved in AA including adenosine 
A1 receptor [2], cannabinoid B2 (CB2) receptor [3] as well as other multiple, 
distinctive neurobiological mechanisms summarized by Zhao [4]. Additionally, 
anti-inflammatory effects of EA were also demonstrated by previous researchers [5-10] 
by assessing the increased circumference of paw with inflammation as well as 
quantification of pro-inflammatory cytokines. Endogenous opioid-dependent analgesia 
at spinal cord level was initially associated with mechanisms of AA [11-14]. 
Subsequent studies extended the investigations on pivotal role of endogenous opioids 
in mediating the AA via application of antibodies (Abs) of opioid peptides or opioid 
receptor antagonists at central [15-16] or peripheral level [17-19]. In particular, the 
intensive studies on analgesic mechanism of EA at central level indicated the 
frequency-dependent opioid release by EA, among which an alternative frequency 
mode 2/100 Hz was speculated and found to be significantly more effective than the 
pure low- (2 Hz) or pure high-frequency (100 Hz) therapy [15] (Fig. 1). By comparison, 
the correlative mechanisms between AA and peripheral opioid-mediated analgesia are 
still largely unknown. 
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Fig. 1: Frequency-dependent opioid mechanisms of electroacupuncture-induced 
analgesia in central nervous system (CNS). Representatives (2, 15 and 100 Hz) of 
three different frequencies (low, middle and high frequencies) were compared. The 
neuropeptides (opioid peptides) release was measured by radioimmunoassay on 
perfusate of subarachnoid space of spinal cord. There was a sharp difference exists 
between the 2 and 100 Hz frequency. In a chart with a log scale, 15 Hz is in the 
middle point between 2 and 100 Hz, which can partially activate both sides, leading to 
antinociceptive and other therapeutic effects (EM: endomorphin, ENK: 
met-enkephalin, EP: beta-endorphin, DYN: dynorphin, //: mu/delta/kappa opioid 
receptor) (Figure and legend were modified from Fig. 2 in [15]). 
 
1.2 Comparison of different modes of electroacupuncture 
(EA) treatment 
In order to obtain the ideal effect from acupuncture treatment, a clear and correct 
acupoint positioning approach and needling techniques are the most important factors. 
This is in line with the acupuncture-induced sensation ‘De Qi’ majorly referring to 
subjective responses to needling including soreness, numbness, distension and aching 
(dull pain in deep tissue) [1]. Addressing these issues requires relatively precise 
localization and the effects can be felt best on conscious subjects. Nevertheless, 
needling on conscious subjects, especially animals, is considered to be stressful. An 
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anesthetic or restrainer was therefore often utilized on animals during needling in order 
to mitigate the treatment discomfort [2,20-22] (Fig. 2 and 3). However, the effects 
from either anesthetics or restrainers are difficult to estimate and would probably 
impair treatment effect or biological and psychological conditions. 
 
As one of the frequently used acupoints in clinical settings, GB-30 Huantiao (GB: the 
Gallbladder Meridian of Foot-Shaoyang; Chinese name in pinyin: Huantiao) is 
thought to be effective in treating symptoms or disease referenced to lower limbs- and 
lower back-related pain and thus frequently employed in scientific investigations 
[3,16,22-24]. The precise anatomical location of GB-30 Huantiao on humans is clearly 
known and easy to find, however the exact procedures to accurately locate the 
corresponding point in rats has not been very well described by pervious researchers 
[3,16,22-24]. 
 
 
Fig. 2: Acupuncture procedure by two experimenters and EA treatment on rat in 
semi-free restrainer. The animals were gently handled for 30 min each day for 2-3 
days and habituated to the acupuncture treatment before the experiment. [A] After 
cleaning the skin with alcohol swabs, disposable acupuncture needles with electrodes 
soldered to their handles were swiftly inserted bilaterally, approximately 1/2 in deep, 
into GB-30 Huantiao by one investigator while the other gently held the animal. The 
needles and the electrodes were stabilized with adhesive tape. The procedure typically 
lasted less than 20 s and caused little distress to the animal. [B] The EA stimulation 
was delivered by an electrical stimulator via an isolator to convert electrical voltage 
into constant electrical current (Figure and legend were modified from Fig. 1 in [16]). 
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Fig. 3: EA treatment was performed on fully restrainer-stabilized rats. Rats were 
kept in a special transparent Lucite barrel with tails and hind-legs left out naturally. 
The Lucite barrels were designed to restrict rats and ensure the successful EA 
operations to these clearheaded rats. In order to minimize the bias effect induced by 
barrel restraint, rats were placed quietly for 15 min to be stabilized and were given 
different EA treatments in groups (Figure and legend were modified from Fig. 3 in 
[21]). 
 
1.3 Tonic analgesia mediated by peripheral opioid peptides 
containing-immune cells 
“In the local inflammatory pain model induced by CFA, opioid peptide-containing 
leukocytes migrate into the inflamed tissue and release opioid peptides. Opioid 
peptides bind to opioid receptors on peripheral nociceptive neurons and mediate a 
peripheral analgesic effect. This analgesic effect elicited by exogenous triggers e.g. 
cold-water swim stress or local injection of certain cytokines (e.g. tumor necrosis factor 
(TNF)-alpha, interleukin (IL)-1beta), chemokines (CXCL2/3) (Fig. 4), 
corticotrophin-releasing hormone/factor (CRH/CRF), or formyl peptides (Fig. 5) 
[25-28] could only last for a short period (10-20 min), which partly hampers clinical 
application” [5]. 
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However, previous studies indicated that opioid peptides were continuously released 
from opioid peptide-containing leukocytes at the inflammatory site and attenuate 
inflammatory pain via formyl peptide receptors on neutrophils in an early phase (2 h) of 
CFA [29] (Fig. 5) which partially answered clinical and experimental postulations for 
tonic analgesia [30,31]. As illustrated before, accumulating evidences have supported 
acupuncture elicited analgesia via opioid receptors/peptides. Nevertheless, in all 
publications to date the pre-EA application mode of antagonists/Abs of opioid 
receptors/peptides could only manifest opioid-dependent acute analgesia of 
acupuncture. The question of how sustained (tonic) analgesia of acupuncture can exist 
remains, illustrated through the large number of publications in this area. 
 
 
Fig. 4: Chemokine receptor CXCR2 and ligand CXCL2/3 attenuates peripheral 
inflammatory pain via opioid peptide-containing polymorphonuclear cells 
(PMNs, neutrophils) at early phase (2 h) of CFA. Chemokine CXCL2/3 released 
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from endothelium blood vessel binds to CXCR2 expressed on neutrophils, leading to 
Ca2+ influx from the endoplasmic reticulum (ER) of neutrophils via activating p38 
mitogen-activated protein kinase (MARK) and phosphoinositol-3-kinase (PI3K). The 
increased intracellular level of Ca2+ leads to opioid peptides release from neutrophils. 
Opioid peptides binding to opioid receptors on nociceptor of peripheral sensory 
neurons induces peripheral antinociception (PLC: phospholipase C, IP3: inositol 1, 4, 
5-triphosphate) (Figure and modified legend were cited from [27]). 
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Fig. 5: Opioid peptide-containing neutrophils mediate tonic analgesia at early 
phase (2 h) of CFA. Mycobacterial components (blue square) formyl peptides and 
lipoproteins /lipomannans respectively bind to formyl peptide receptor (FPR, orange) 
and toll like receptor (TLR) 2/4 (orange) on neutrophils (with light blue segmented 
cell nucleus). Formyl peptides-FPR binding activated PI3K and Ca2+ influx, leading to 
continuous secretion of opioid peptides (green rhomboids) from neutrophils. The 
continuous released opioid peptides binding to opioid receptors (brown) on nociceptor 
of peripheral sensory neurons (yellow) thereby produces tonic analgesia continuously 
attenuating peripheral inflammatory pain (Boc-FLFLF/Cyclosporine H: antagonists of 
FPR, Wortmannin: inhibitor of PI3K, BAPTA/AM: intracellular Ca2+ level inhibitor 
(chelator highly selective for Ca2+ over Mg2+), Naloxone/CTOP (Cys2, Tyr3, Orn5, 
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Pen7-amide)/NTI (naltrindole): antagonists of mu/delta receptor, Ab: antibody) 
(Figure and modified legend were cited from [29]). 
 
1.4 Cytokine-mediated hyperalgesic and anti-hyperalgesic 
responses in pain 
A broad set of publications in the last few decades supported the hyperalgesic role of 
pro-inflammatory cytokines and anti-hyperalgesic property of anti-inflammatory 
cytokines during inflammation. Since SH Ferreira and his colleagues first reported the 
potent nociceptive effect IL-1beta in non-inflamed paw [32], they produced 
subsequent studies which expanded this cytokine spectrum that deteriorates the 
inflammatory hyperalgesia to TNF-alpha and IL-6 [33]. TNF-alpha also evoked 
mechanical allodynia in a neuropathic pain model [34]. The anti-hyperalgesic action 
of anti-inflammatory cytokines including IL-4, IL-10 and IL-13 were separately 
investigated in carrageenan or bradykinin – induced hyperalgesia via application of 
inhibitory Abs of cytokines in vivo and in vitro, which notably decreased the 
nociceptive intensity in vivo and suppressed the production of IL-1beta and 
TNF-alpha in vitro [35-37]. It was also demonstrated that IL-13 induced MOR 
expression in lymph nodes from patients with T cell lymphoma, which might be 
beneficial for down-modulating immune response [38]. 
 
Apart from the large body of references emphasizing the hyperalgesic role of 
pro-inflammatory cytokines, notably, some pro-inflammatory cytokines were also 
recognized as antinociceptive. TNF-alpha as well as IL-1beta was indicated to 
opioid-dependently elicit transient but potent mechanical antinociception in vivo 
[25,28]. Intracerebroventricular administration of IL-1alpha could inhibit thermal 
hyperalgesia, which might be mediated by CRH and the noradrenergic system [39]. 
Generally speaking, the current knowledge referring to the hyperalgesic or 
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anti-hyperalgesic role of cytokines might be considerably reliant on specific 
circumstances and inflammatory phases in different models. 
 
1.5 Aims 
The current existing, intriguing conclusions of opioid-dependent AA and 
cytokine-mediated roles in pain inspired the initial aims of this thesis with 
discovering: 
1. Which parameter setting of EA is beneficial for achieving optimal EA-induced 
sustained (tonic) antinociception and whether the EA treatment could be 
accomplished under free-moving rats. 
2. Whether EA produced tonic antinociception is peripheral opioid 
receptor/peptide-dependent. 
3. Whether EA could regulate local cytokines, and of regulated cytokines, which 
key cytokine contributes to tonic AA as well as the possible immune and 
peripheral opioid-correlated mechanism. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
Table 1: Abbreviations and companies of applied chemicals 
Chemicals Companies 
Acrylamide/Bis (30:2) 
Agarose  
Albumine from bovine serum (BSA) 
Ammonium persulfate (APS)  
Aprotinin 
Bestatin 
Beta-Mercaptoethanol 
Bromophenol Blue 
Chloroform 
Collagenase 
Complete Protease Inhibitor Cocktail 
Cytochalasin B 
DAPI (4',6-diamidino-2-phenylindole) 
Enhanced chemiluminescence solution (ECL) 
detection reagent 
Ethanol 
Ethylenediaminetetraacetic acid (EDTA) 
Ethylene glycol tetraacetic acid (EGTA) 
Glycerol 
Hank's Balanced Salt Solution (HBSS) 
HEPES 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
Heparin 
Hyaluronidase 
Carl Roth GmbH, Karlsruhe, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
Carl Roth GmbH, Karlsruhe, Germany 
Sigma-Aldrich, Munich, Germany 
Roche Diagnostics, Mannheim, Germany 
Sigma-Aldrich, Munich, Germany 
Roche Diagnostics, Mannheim, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
Roche Diagnostics, Mannheim, Germany 
 
Merck, Darmstadt, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
 
Rotexmedica GmbH, Trittau, Germany 
Sigma-Aldrich, Munich, Germany 
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Imidazole hydrochloride 
Isopropanol 
Magnesium chloride (MgCl2) 
Nonfat-Dried Milk bovine 
Paraformaldehyde (PFA) 
Phenylmethanesulfonyl fluoride (PMSF) 
Phosphate buffered saline (PBS, sterile, 0,1M, pH 
7.4) 
Potassium chloride (KCl) 
Roswell Park Memorial Institute (RPMI) 1640 
 
Saponin 
Sodium azide (NaN3) 
Sodium chloride (NaCl) 
Sodium dodecyl sulphate (SDS) 
Sodium fluoride (NaF) 
Sodium molybdate (Na2MoO4) 
Sucrose 
Tetramethylethylenediamine (TEMED) 
Thioglycolate 
Thiorphan 
Tissue-Tek compound  
Tris hydroxymethyl aminomethane (Tris)  
Triton X-100 
Trypan Blue 
TRIzol® 
 
Tween20 
Carl Roth GmbH, Karlsruhe, Germany 
Merck, Darmstadt, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
Biochrom AG Biotechnologie, Berlin, 
Germany 
Carl Roth GmbH, Karlsruhe, Germany 
Invitrogen/Life Technologies, Darmstadt, 
Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
Merck, Darmstadt, Germany 
Carl Roth GmbH, Karlsruhe, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, Germany 
OCT, Miles, Elkhart, Indiana, USA 
Sigma-Aldrich, Munich, Germany 
Sigma-Aldrich, Munich, German 
Sigma-Aldrich, Munich, German 
Invitrogen/Life Technologies, Darmstadt, 
Germany 
Sigma-Aldrich, Munich, Germany 
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2.1.2 Antibodies (Abs) 
Table 2: Suppliers and doses of primary Abs (Behavior: behavioral assays, WB: 
western blot, FACS: fluoresces-activated cell sorting, IHC: 
immunohistochemistry staining, BD PharmingenTM: Pharmingen/Becton 
Dickinson, KOR: kappa opioid receptor) 
Primary Abs Companies Concentrations Applications 
Behavior WB FACS IHC 
Rabbit anti-END 
Rabbit anti-ENK 
Rabbit anti-DYN 
Peninsula 
Laboratories 
Merseyside, UK 
2 g/100 l 
1.25 g/100l 
1 g/100l 
X 
X 
X 
   
Rabbit 
anti-CXCL10 
Peprotech 
Hamburg 
Germany 
 2 g/100l X    
Rabbit anti-END 
Rabbit anti-ENK 
Rabbit anti-DYN 
Peninsula 
Laboratories 
Merseyside, UK 
 
1:1000 
   X 
X 
X 
Mouse anti-CD68 
 
 
Rabbit 
anti-macrophages 
antiserum 
 
Mouse anti-CXCR3 
Serotec 
Düsseldorf, 
Germany 
Cedarlane 
Laboratories, 
Ontario Canada  
My Biosource, 
San Diego, 
USA 
1:400 
 
 
1:200 
 
 
1:500 
   X 
 
 
X 
 
 
X 
Mouse anti-CD45 
Mouse anti-CD3 
BD 
PharmingenTM, 
Heidelberg, 
Germany 
0.2 g/l 
0.5g/l 
  X 
X 
 
Mouse anti-CD68 Serotec 
Düsseldorf, 
Germany 
0.1 g/l   X  
Mouse anti-MOR 
Rabbit anti-KOR 
Abcam, 
Cambridge, UK 
1:500 
1:1000 
 X 
X 
  
Rabbit anti-DOR Neuromics, 
MN, USA 
1:250  X   
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Table 3: Suppliers and doses of secondary and control Abs 
Secondary or 
control Abs 
Companies Concentrations Applications 
Behavior WB FACS IHC
Rabbit IgG  
(IgG control) 
Peninsula 
Laboratories 
Merseyside, 
UK 
2 g/100l X    
Donkey anti-mouse 
Ab  
(both secondary Abs)
Goat anti-rabbit Ab 
Vector 
Laboratories, 
Burlingame, 
CA 
 
1:250 
    
X 
Mouse IgG1 
(both isotype 
controls) 
Mouse IgG3 
 
BD 
PharmingenTM
 
0.5g/l 
   
X 
 
Anti-mouse Ab 
(both secondary Abs)
Anti-rabbit Ab 
GE 
Healthcare, 
München, 
Germany 
Roche, 
Mannheim, 
Germany 
1:5000 
 
 
1:3000 
 X 
 
 
X 
  
Mouse anti-GAPDH
(control Ab) 
Millipore, 
Schwalbach, 
Germany 
1:2000  X   
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2.1.3 Additional drugs for peripheral administration 
Table 4: Doses and suppliers of other drugs for intraplantar (i.pl.) 
administration 
Drugs Doses (i.pl.) Suppliers 
Complete Freund's adjuvant 
(CFA) 
150 l Calbiochem, San Diego, 
CA, USA 
Naloxone hydrochloride 
dehydrate (NLX) 
0.56 ng/100 l Sigma-Aldrich, Munich, 
Germany 
Naltrindole hydrochloride 
(NTI) 
25 g/100 l Sigma-Aldrich, Munich, 
Germany 
Recombinant rat IP-10 
(CXCL10) 
0.2 ng/100 l Peprotech, Hamburg, 
Germany 
Sodium chloride (0.9% 
NaCl solution) 
100 l B. Braun Melsungen AG, 
Melsungen Germany 
 
2.1.4 Kits 
Table 5: Suppliers of all kits 
Kits (application) Companies 
Rat TNF-alpha kit (ELISA) 
Rat IL-4 kit (ELISA) 
High-Capacity cDNA Reverse 
Transcription Kit (RT-PCR) 
 
Invitrogen/Life Technologies, 
Darmstadt, Germany 
Rat Cytokine Array kit (Cytokine Array) 
Rat IL-1beta kit (ELISA) 
Rat IL-1alpha kit (ELISA) 
Rat IFN-gamma kit (ELISA) 
 
R&D systems, London, UK 
Rat IL-13 kit (ELISA) Abcam, Cambridge, UK 
Rat IP-10 (CXCL10) kit (ELISA) Peprotech, Hamburg, Germany 
Pierce BCA protein assay kit (WB) Thermo Fisher Scientific, Ulm, 
Germany 
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Rat beta-END kit (ELISA) Phoenix Pharmaceuticals, Inc., 
Karlsruhe, Germany 
 
2.1.5 Experimental software and hardware 
Table 6: Suppliers and application of software for experimental analysis 
Software Companies Application 
Sigma plot 11.0 Systat Software GmbH, 
Erkrath, Germany 
Statistical analysis and graphing
EndNote X6 Thomson Reuters GmbH, 
Philadelphia, PA, USA 
References managing 
 
Sunrise® Tecan 
 
Tecan Deutschland GmbH, 
Crailsheim, Germany 
ELISA plate reader and data 
analysis; 
WB (Pierce BCA protein assay 
kit) 
7300 System Sequence 
Detection Software v1.4.0 
Applied Biosystems GmbH, 
Darmstadt, Germany 
PCR amplification and analysis
FluorChem FC2 
MultiImage II 
Alpha-InnoTech, Kasendorf, 
Germany 
WB image scanning and 
densitometric analysis 
NIH Image J software Bethesda, MD, USA IHC image analysis 
CellQuest BD PharmingenTM FACS staining analysis and 
graphing 
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Table 7: Suppliers and application of hardware for experiment performance 
Hardware Companies Application 
AS Super_4_digital electrical 
stimulator 
Schwa-medico, 
Ehringshausen, Germany 
Electric stimulation 
Randall-Sellito Analgesiemeter  
(Modified Randall-Sellito test) 
 
Ugo Basile, Comerio, Italy 
 
Mechanical nociceptive 
test 
IITC Plantar 
(Hargreaves Method) 
IITC Inc/Life Science, 
Woodland Hills, CA, USA 
Thermal nociceptive test
Thermometer (TM99A) Cooper-aktins, FL, USA Paw temperature 
measurement 
Plethysmometer (37140) Ugo Basile, Comerio, Italy Paw volume 
measurement 
Sunrise® Tecan Tecan Deutschland GmbH, 
Crailsheim, Germany 
ELISA plate reader 
7300 System Sequence 
Detection hardware 
Applied Biosystems GmbH, 
Darmstadt, Germany 
RT-PCR amplification 
GeneAmp® PCR System 9600 
thermal cycler 
Applied Biosystems GmbH, 
Darmstadt, Germany 
cDNA transcription 
Eppendorf Thermalmixer® Eppendorf AG, Hamburg, 
Germany 
RNA isolation 
peqPOWER 300 Volt Power 
Supply 
PEQLAB Biotechnologie 
GmbH, Erlangen, Germany 
Electrophoresis (WB) 
FluorChem FC2 MultiImage II Alpha-InnoTech, Kasendorf, 
Germany 
WB image scanner 
Tissuelyser (and sterilized 
stainless steel beads) 
Qiagen, Düsseldorf, Germany Paw tissue 
homogenization (WB 
and RT-PCR) 
Cryostat (MicroTM HM 525) Thermo Fisher Scientific, Ulm, 
Germany 
Tissue slice preparation 
for IHC 
Zeiss 510META laser scanning 
microscope 
Zeiss AIM, Jena, Germany IHC image obtaining 
and graphing 
FACS Scan BD PharmingenTM FACS staining analysis
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2.2 Experimental methods	
2.2.1 Peripheral inflammatory pain model on animals 
Male adult Wistar rats weighing 280-350 g were housed collectively in rat cages (6 per 
cage) under controlled experimental conditions with free access to food and drink. All 
research schemes were approved by the University of Würzburg associated animal 
care committee. Experimental procedures were conducted strictly in accordance with 
the recommendations of the International Association for the Study of Pain [40]. 
Isoflurane was applied as an anesthesia for all pharmacological interventions. 
Inflammatory pain was triggered by administration (i.pl.) of 150 µl CFA in the plantar 
of right paw of all rats in accordance with previous investigations [41]. Rats were 
required to be sacrificed by an overdose of CO2 or T61 (a veterinary euthanasia drug 
made with embutramide) up to 144 h post CFA injection according to animal ethical 
committee. 
 
2.2.2 Establishment of EA treatment 
In order to ease the rats during treatment, repeated handling work for 3-4 days prior to 
the experiments was performed on rats 3 times per day. Experimental rats were gently 
handled within a man-made covering which was formed from a piece of 
pre-disinfected paper (same handling approach as showed in Fig. 7A, B). 
 
Before experiments, all properly handled and randomly selected rats were divided into 
three experimental groups including CFA + EA (CFA rats with EA treatment), CFA + 
sham (CFA rats with sham-EA treatment) and CFA control (CFA). The adjacent hair 
of the lower back area close to GB-30 Huantiao was cleanly removed by a shaver. 
Before needle insertion, adjacent skin upon acupoint GB-30 Huantiao was completely 
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disinfected to avoid infection; GB-30 Huantiao was anatomically located in 
accordance with the established 3D modeled position. The hiatus sacral of rats is 
comparable to the last sacral vertebra on the human body. The bony landmarks to 
position GB-30 Huantiao consisting of the last sacral vertebrae and the great trochanter, 
were firstly palpated and marked up (bilateral black circles and last vertical black 
circle in Fig. 6A, B). Commercially purchased disposable acupuncture needles with a 
diameter of 0.20 mm and needle body length of 25 mm were used (Schwa-medico, 
Ehringshausen, Germany) and connected with an electrical stimulator. The depth and 
direction of the needle had to be carefully regulated in case the rat was irritated by the 
unbearable stimulus from the insertion as well as the electricity. During the first 1 min, 
the electrical current was quickly turned up to 1 mA, which induced a minor twitching 
of the limbs (Fig. 6C). At this point, tiny adjustments were still necessary if the rat 
was agitated by the treatment. To guarantee the complete freedom of movement of the 
rats during this stage of the experiment, the electrical current needed to be 
appropriately and slowly increased from 2 up to 3 mA in a pattern of 0.1 mA (Fig. 6D). 
Precise values of electrical intensity were variable according to individual tolerance, 
however normally within a range of 2-3 mA. In most cases, indication of correct 
performance on the GB-30 Huantiao could be described as gentle twitching of the 
entire hind limb including the paw due to an indirect stimulus on the sciatic nerve 
lying the underneath the GB-30 Huantiao. Sham EA rats received same treatment, with 
the exception of the electrical current being omitted. It is of worth to be noted that 
needling performance requires repeated practice with a premise to tame the rats 
through a correct handling method within the paper covering. The possibility to move 
freely has to be guaranteed to each rat to exclude bias from unequal treatment 
conditions in all the experiments. 
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Fig. 6: Acupoint position and EA treatment on fully conscious free-moving rats. 
[A] Rat was gently handled in a pre-disinfected paper covering at least three days 
before the experiments and needling area was shaved and disinfected. [B] The bony 
marker of last four lumbar vertebral spinous processes (four black dots in a row) and 
the great trochanter (bilateral black dots) were palpated as marked on the graph. The 
accurate anatomical position of GB-30 Huantiao (bilateral yellow dots) on rats was 
located at the junction of lateral 1/3 and medial 2/3 of the distance between the great 
trochanter and the last sacral vertebra. [C] A pair of cables connected acupuncture 
needles was quickly penetrated through the surface skin. Entire needles were vertically 
inserted underneath skin adjacent subcutaneous tissue. Electrical intensity was 
adjusted to 1 mA within first 1 min. [D] Rat was allowed free mobility in the cage 
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following needle insertion. During the next 4 min, electrical intensity was gradually 
increased to 2 mA, with a maximal intensity at 3 mA (Figure and legend were 
modified from Supplementary Fig. 1 in [5]). 
 
2.2.3 Institution of computer-based three-dimensional (3D) rat model 
Based on the anatomical features of Wistar rats, an accurate and reproducible 3D rat 
model was created by Maya 2012 (Autodesk, San Raphael, CA, USA) in aim of 
vividly exhibiting acupoint positioning methods and EA performance on the GB-30 
Huantiao. An initial photograph of a Wistar rat was firstly edited in Adobe Photoshop 
7.0 with an manual transformation into professional 3D image using computer 
programmer-based software Maya 2012. The image was based on the skeleton’s shape, 
relative locations and size of each section exhibited in the original rat photo and was 
then automatically generated and used as a reference point for the following 
procedures. The creation of a digital 3D rat model was based on node-based theory in 
addition to NURBs (non-uniform rational B-spline) and polygon [5]. 
 
In the following procedures, based on the reference image, each section of the rat 
model was re-generated according to node-based theory composing NURBs and 
polygon. The NURBs and polygon were employed to sketch the shape and size of 
each section, e.g. the principle part of the rat model was initially generated from a 
polygon sphere and a column, which was then appropriately reshaped to four limbs. 
For the sketching of each section, the precise mathematical parameters of each node 
(the term “node” is considered as a “unit composing the entire model”) from width (X 
axis) to height (Y axis) as well as depth (Z axis) were appropriately and 
proportionally defined in accordance with the size, skeleton and the angle of each 
individual section of the photographed rat in original picture. Subdivisions of each 
section were then accurately constructed within the given 3D space and this 
developed into a pilot 3D rat model. 
 
In line with its anatomical location and bilateral acupuncture needles, the sciatic nerve 
underneath the GB-30 Huantiao was precisely mapped on the junction of lateral 2/3 
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and medial 1/3 on the line between the great trochanter and last sacral vertebrae. With 
this, an entire rat model was ultimately displayed in a 3D perspective. 
(Patent application is on the review) 
 
2.2.4 Drug delivery 
A volume of 150 l complete Freund’s adjuvant (CFA) was i.pl. administered on the 
right plantar of all rats in order to trigger local inflammatory pain. Following drugs 
were injected with a volume of 100 l dissolved in solvent. Naloxone hydrochloride 
dehydrate (NLX, MOR antagonist), naltrindole hydrochloride (NTI, DOR antagonist) 
as well as Abs against opioid peptides (anti-END, -ENK, or -DYN) were i.pl. 
administered in post-EA at late phase of CFA (96 h). Recombinant rat CXCL10 or 
rabbit anti-rat CXCL10 was either singly (96 h) or daily (day 0 to 4) i.pl. administered. 
Dose ranges of NLX and NTI were selected according to the previous studies [29]. 
Optimal doses of opioid peptide Abs (anti-END, -ENK and -DYN) were based on 
previous studies as well as pilot experiments [29,42]. Selected doses of CXCL10 and 
anti-CXCL10 were established in preliminary experiments. The same amount of 
solvent saline (0.9% NaCl solution) or an identical dose of rabbit IgG was used as a 
control for all experimental groups. 
 
2.2.5 Measurement of nociceptive thresholds (Behavioral assays) 
Paw withdrawal latency (PWL, Hargreaves method) indicating thermal nociceptive 
thresholds were measured in accordance with earlier publications [29]. To describe the 
method: at least three days before the experiments, rats were placed and habituated in 
independent plastic-made containers, situated upon a glass plate. A beam of yellow 
light was emitted from a mobilized light producing beamer pointing at the plantar of 
the rats. The intensity of the light and cut-off point could be properly adjusted. Time 
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(s) was automatically recorded during the measurement. The tolerable time (s) before 
the rat withdrew the paw was considered as the thermal nociceptive threshold. The 
bearable time for non-inflamed paw was established as 20 s as a baseline threshold. 
The cut-off point was set 30 s to avoid tissue damage. The average of raw values of two 
measurements (with 20 s intervals) was calculated for statistical analysis. 
 
Paw pressure threshold (PPT, modified Randall-Sellito test) indicating mechanical 
nociceptive threshold was measured according to previous studies [29]). For at least 
three days prior to the experiment, experimental rats were repeatedly handled in a 
man-made paper covering as photographed in Fig. 7A, B, the same handling method 
that was utilized when nociceptive assessment was performed (Fig. 7C, D). The 
manually generated pressure was continually increased on a randomly chosen point 
on the dorsal surface of hind paw. The pressure (g) that caused the rat to retract its paw 
suggested the mechanical nociceptive threshold. 250 g was set up as the cut-off point 
in order to prevent tissue damage. There was a 10 s interval between each 
measurement to ensure the accuracy of the values. The average of raw values of three 
nociceptive thresholds was calculated and applied for statistical analysis.  
 
A statistically decreased value of the nociceptive threshold normally indicates 
hyperalgesia (increased sensitivity to pain) and statistically increased values normally 
suggest anti-hyperalgesia (= antinociception or analgesia, decreased sensitivity to 
pain). The differences between the pain-related terms are illustrated further in Table 8. 
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Fig. 7: Measurement of paw pressure threshold (PPT). [A] Healthy male Wistar 
rats were used. Handling was repeatedly performed at least three days prior to 
behavior experiments to guarantee the rats used to the experimenter. [B] Rats were 
hold in the hand softly by using a natural and comfortable position for them. [C] For 
evaluation of the withdrawal response to pressure, a modified Randall and Sellito 
apparatus was used. One of its hind paws was placed on the test pad slowly and then 
the plastic piston was placed on the dorsal surface of the paw softly. [D] An 
incremental pressure was continuously applied by a blunt piston of surface area 1.75 
mm2 until the rat withdrew its paw, the weight (g) recorded was the mechanical 
nociceptive threshold. The pressure test was applied on three different points on the 
dorsal surface of each paw and with 10 s interval between each test. The mean value 
was then determined from three tests (Modified from mini-thesis of Ying Wang 
“Effect of Resolvin D1 and chemerin upon nociception in local inflammation induced 
by complete Freund’s adjuvant”). 
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Table 8: Definitions of pain-related terms (Modified from Table 1 in [43]) 
Terms Definition 
Nociception The neural processes of 
encoding and processing 
noxious stimuli 
Antinociception 
(Applied on animals) 
An increase in pain threshold to 
a stimulus that is normally 
painful 
Hyperalgesia A decrease in pain threshold to 
a stimulus that is normally 
painful 
Anti-hyperalgesia An increase in pain threshold to 
a stimulus that is normally 
painful 
Analgesia 
(Applied on human) 
An increase in pain threshold to 
a stimulus that is normally 
painful 
Allodynia Pain evoked by a stimulus that 
does not normally provoke pain 
Nociceptive/hyperalgesic 
behavior test 
Behavioral responses to 
noxious stimuli 
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2.2.6 Measurement of paw temperature and volume 
The surface temperature of the plantar skin was measured with a contact Thermometer 
sensor before (0 h) and 6 d (144 h) post CFA injection. The volume of the hind paw was 
measured by submerging the entire hind paw to the tibiotarsal joint inside a water-filled 
Perspex cell of a Plethysmometer, and the connected professional volume reader 
displayed the exact value in mm2. The measured values of temperature and volume 
divided baseline values were multiplied by 100 (values ÷ baseline × 100); the average 
value of two measurements was manually calculated and used for statistical analysis. 
Experimental procedures measuring paw volume and temperature were conducted 
referring to previous research [44,45]. 
 
2.2.7 Cytokine Array and enzyme-linked immunosorbent assay 
(ELISA) 
Sample preparation: At 96 h post CFA, rat subcutaneous paw tissue was collected by 
a sharp scalpel and immediately minced in cold lysis buffer containing a complete 
Protease Inhibitor Cocktail (dissolved in PBS, pH 7.4, one tablet/10 ml lysis buffer) 
(Table 9). Homogenate samples were kept on ice until being transferred into a -80°C 
freezer. One day before further usage for cytokine detection, the frozen homogenate 
was taken out from the freezer and transferred into a 4°C fridge and left overnight, 
allowing complete cytokine release from incubated cells in tissue lysates. Tissue 
lysates were centrifuged at 14×1000 g for 10 min to remove the debris, and the 
supernatant was aliquoted and prepared for further application on Cytokine Array to 
detect relative expression levels of individual cytokine analytes, or ELISA in order to 
assess the quantified concentrations of individual cytokines. Procedures for sample 
preparation were conducted according to [45]. 
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Rat Cytokine Array: Cognate immobilized capture Ab was pre-coated on the 
membrane of the Rat Cytokine Array kit. The sample supernatant and detection Ab 
mixture was then incubated. Cytokine antigen and detection Ab complex were bound. 
After removing the unbounded capture Ab on the membrane, Streptavidin-horseradish 
peroxidase (SA-HRP) was then subsequently added. The membrane was visualized 
using enhanced chemiluminescence solution (ECL) by FluorChem FC2 MultiImage II. 
Integrated density value (IDV) of duplicated spots (representing individual cytokine 
according to the datasheet) was analyzed with FluorChem FC2 MultiImage II. The 
percentage of intensity of each cytokine level relative to the positive control was 
calculated and analyzed by statistical software. 
 
Individual ELISA kits: Each kit for measuring IL-1alpha, IL-1beta, IFN-gamma, 
CXCL10, TNF-alpha, IL-4 or IL-13 was used according to the manufacturer’s 
instructions. A general summary for the principles of ELISA including all applied kits 
in this thesis: a specific capture Ab of one cytokine was pre-coated on the wells of the 
microplate provided in each kit and nonspecific binding sites were blocked. Standards, 
controls and samples were pipetted into the wells sequentially, and any cytokine 
antigen presented would simultaneously bind to the immobilized pre-coated captured 
Ab. Unbound reagents were removed by a wash buffer after a specific enzyme-linked 
Ab was added. Following the addition of subtract solution, which acted on the bound 
enzyme to produce color; the intensity of the color was proportionally determined by 
the level of the targeted cytokine bound complex. The addition of sulfuric acid stopped 
the solution changing the color, enabling accurate measurement of the intensity of the 
targeted cytokine bound complex at 450 nm using an ultraviolet/visible (UV/Vis) 
spectrophotometry (Sunrise® Tecan). A standard curve was automatically drawn from 
a serial dilution of known-concentration solution of the target molecule. The 
concentration for each sample was automatically calculated referring to the optical 
density (O.D.) values that were compared to standard curve. The measured 
concentration of each sample was multiplied by its respective dilution factors if 
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samples have been diluted prior to the assay and then further applied for statistical 
analysis. 
 
Table 9: Ingredients of tissue lysis buffer 
20 mM Imidazole hydrochloride 
100 mM KCL 
1 mM MgCl2 
10 mM EGTA 
1 mM EDTA 
10 mM NaF 
1 mM Na2MoO4 
1.0% Triton X-100 
0.1 M PBS, pH 7.4 
 
2.2.8 RNA extraction, cDNA transcription and reverse transcription- 
polymerase chain reaction (RT-PCR) 
RNA extraction: At 72 and 96 h post CFA, rat subcutaneous paw tissues were 
collected, following an immediate translocation into a -80°C freezer until proceeding 
with RNA extraction. Before RNA isolation, the tissue samples were thawed on ice 
after adding 1ml TRIzol® and were subsequently homogenized with sterilized 
stainless steel beads (5 mm) from Tissuelyser (frequency: 20 Hz, time: 4 min) [45], and 
then kept on ice for 6 min in order to completely release the protein, DNA and RNA. 
200 l of chloroform was added in order to form the detached phases. The upper 
phase containing the RNA was collected and transferred into a fresh tube with 500 l 
isopropanol (100%) inside. Following complete vortex, RNA was kept in isopropanol 
at -20°C overnight (maximal 4 days). On the second day, RNA was centrifuged 
(13.6×1000 rpm, 5 min, 4°C), the obtained RNA enriched supernatant was washed 
with 75% ethanol. It was subsequently spun down and centrifuged (5.2×1000 rpm, 
5min, 4°C) in order to get a RNA pellet loaded tube, which was further dried at 37°C 
for 10 min and resuspended in 100 l nuclease free water. The final suspension was 
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incubated in Eppendorf Thermalmixer® (1.4×1000 rpm, 57°C) for 10 min, and then 
aliquoted and stored in -80°C before cDNA transcription. 
 
cDNA transcription: 10 l cDNA of a mixture volume of cDNA reagent was 
aliquoted into a 96-well reaction template. Components from High-Capacity cDNA 
Reverse Transcription Kit for the reaction plate were described in Table 10. After 
calculating the extracted RNA concentration, an equal volume of 10 l master mix as 
well as a corresponding volume (l) of 1 µg purified RNA was sequentially added and 
reversely transcribed into cDNA according to a well established program with the 
Thermal cycler (25°C for 10 min, 37°C for 120 min, 85°C for 5 min) and was held at 
4°C. cDNA products were aliquoted and kept at -80°C before PCR amplification. 
 
RT-PCR: 25 l of PCR reaction mixture were shown in Table 11 amplified by 
RT-PCR with Taqman gene expression assays for rat CXCL10 (labeled with FAM; 
Assay ID: Rn01413889_g1) and GAPDH (glyceraldhyde-3-phosphate dehydrogenase, 
labeled with VIC) as a housekeeping gene. FAM or VIC refers to specific compatible 
fluorescein-based 5’ end reporter dye. Sequences of FAM/VIC labeled primers were 
kept confidential from Invitrogen/Life Technologies. Thermal cycling conditions were 
established according to the manufacturer’s instructions: 50 cycles of melting for 15 s 
at 95°C and followed annealing and extension for 1 min at 60°C. Two different 
RT-negative controls were conducted: all the reagents were added with either 1) 
replacement of cDNA by sterilized water or 2) replacement of enzyme mix “ABsolute 
QPCR ROX Mix” (Thermo Fisher Scientific, Ulm, Germany) with sterilized water in 
order to evaluate the contamination from genomic DNA or other sources which would 
lead to artificial positive amplification in reverse transcription reaction. As a result of 
the relatively uniform expression in inflamed and non-inflamed paw tissue compared 
to beta-actin and 18SrRNA in preliminary trials (data not shown), GAPDH was chosen 
as an optimal housekeeping gene control. 
 
Data analysis: CT values were calculated using the 2ΔΔCT method (ΔΔCT = ΔCT sample – 
ΔCT calibrator) for relative quantification (RQ). CT values of inflamed paw normalized 
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to non-inflamed paw were used. ΔCT was calculated by normalized CT values of 
samples minus CT values of GAPDH (calibrator). The relative quantification values 
2ΔΔCT were obtained by individual 2ΔCT dividing the average 2ΔCT values, and further 
applied for statistical analysis. 
 
Table 10: Pipetting scheme of cDNA reaction plate 
Reagent Volume 
Reverse Transcription buffer (10 ×) 2 µL 
Deoxynucleoside triphosphates (DNTPs, 25 ×) 0.8 µL 
MultiScripeTM Reverse Transcriptase  1 µL 
Random primers (10 ×) 2 µL 
Ribonuclease (RNase) Inhibitor 1 µL 
Nuclease-free H2O 3.2 µL 
 
Table 11: Pipetting scheme of PCR reaction template 
Reagent Volume 
ABsolute QPCR ROX mix 12.5 µL 
Taqman gene expression assay (20 ×) 1.25 µL 
Nuclease-free H2O 6.25 µL 
cDNA (1:10 diluted) 5 µL 
 
2.2.9 Immunohistochemistry staining (IHC) 
Tissue preparation: At 96 h CFA, rats were anesthetized with isoflurane and fixed in 
supine position. Right before recovering from anesthesia, rats were transcardially 
perfused with PBS (0.1 M, pH 7.4) containing heparin (0.66 ml heparin in 100 ml 
PBS, 20 ml/rat) to prevent coagulation and then continuously perfused with 4% 
paraformaldehyde (PFA, dissolved in PBS, pH 7.4, 150 ml/rat) (fixative solution) in 
order to remove the blood from circulatory vessels. Procedures were referring to 
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previous investigations [46]. The subcutaneous tissues adjacent to the plantar skin 
were collected from both inflamed and non-inflamed hind paws, post-fixed in the 
same fixative solution for 1.5-2 hours, and then cryoprotected in 10% sucrose solution 
at 4°C overnight. All solutions were freshly prepared prior to experiments. The tissue 
samples were embedded in tissue-Tek compound, and kept frozen in -80°C. 7 m 
thick sections were obtained using Cryostat and mounted on gelatin-coated glass 
slides. 
 
Double immunoflourescence staining: The tissue sections mounted on slices were 
incubated for 60 min in PBS containing 0.3% Triton X-100, 1% BSA, 10% goat 
serum (Vector Laboratories, CA, USA) as blocking solution to prevent nonspecific 
binding. The slices were then incubated overnight with the following primary Abs: 1) 
polyclonal rabbit anti-rat END or -ENK or -DYN (all diluted in 1:1000) in 
combination with monoclonal mouse anti-CD68 (ED1, 1:400) or 2) mouse 
anti-CXCR3 (1:500) in combination with polyclonal rabbit anti-rat macrophage 
antiserum (1:200). After incubation with primary Abs, the tissue slices were washed 
with PBS (3×20 min) and then incubated with Texas red conjugated goat anti-rabbit 
Ab (1:250) in combination with fluorescein isothiocyanate (FITC) conjugated donkey 
anti-mouse Ab (1:250). Thereafter, the tissue sections were washed with PBS, and the 
nuclei were stained bright blue with 4',6-diamidino-2-phenylindole (DAPI) (0.1 µg/ml 
in PBS). Finally, the tissue slices were washed in PBS and mounted in Vectashield 
(Vector Laboratories). To demonstrate specificity of the staining, omission of either 
the primary or the secondary Abs was performed. 
 
Image obtaining and analyzing: After staining, selected sections of all samples were 
scanned and imaged with a confocal laser scanning microscope (LSM). Three fields 
from three samples within one group were pictured and further applied for image 
analysis by NIH Image J software. The percentage of double-labeled macrophages 
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found in all single stained macrophages was calculated for all images. The average of 
three percentage values within one group was used for statistical analysis. Analyzer for 
percentage calculation and statistical analysis was blinded. 
 
2.2.10 Fluorescence-activated cell sorting (FACS) 
Tissue digestion: At the time point of 96 h CFA, rat subcutaneous paw tissues were 
collected. Cellular staining was performed by using the supernatant of homogenized 
tissue fraction for flow cytometry analysis in accordance with previous descriptions 
[26]. Freshly obtained rat subcutaneous inflamed and non-inflamed paw tissues were 
firstly homogenized into 1-2 mm fragments and digested for 1 h in 37°C with a 
digestive solution of 10 ml RPMI 1640 medium containing 30 mg collagenase, 10 mg 
hyaluronidase, and 0.5 ml 1M HEPES (3 ml digestive solution/sample, freshly 
prepared). The digested fragments were then pressed through a 70 m nylon filter (BD 
PharmingenTM) to isolate pure cell suspension from tissue debris. Purified cell 
suspensions were washed with PBS and centrifuged (1.2×1000 rpm, 10 min), 
supernatant was discarded and cell pellet was resuspended in PBS and aliquoted into 
FACS tubes. After centrifuge (1.2×1000 rpm, 10 min), cells were coated on the 
bottom of FACS tube and resuspended in PBS. 
 
Double staining: 
All solutions were freshly prepared prior to experiment. 
1) For extracellular staining: Pure cell suspensions were simultaneously 
incubated with a pre-tested optimal volume of 10 µl mouse anti-rat-CD3-FITC 
(recognizing T cells, 0.5 g/l) and 5 µl mouse anti-rat-CD45-phycoerythrin 
(PE)-Cy5 Ab (identifying all hematopoietic cells, 0.2 µg/µl) for 30 min in 
dark at room temperature (RT), stained cell suspensions were washed by PBS 
and centrifuged (1.2×1000 rpm, 10 min). 
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2) For intracellular staining: Cells were firstly fixed in 1% PFA (30 min, 250 
µl/tube) and cell membrane was permeabilized by saponin (0.5% saponin, 
0.5% BSA, 0.05% NaN3 in PBS). After centrifuge, supernatant was discarded 
and the left 50 µl cell suspensions were simultaneously stained with 10 µl 
mouse anti-rat-ED1-FITC (marking the CD68 antigen expressed on 
monocytes/macrophages, 0.1 g/l) and 5 µl mouse anti-rat-CD45-PE-Cy5 
Ab for 30 min in dark (RT). Saponin and PBS were sequentially used to wash 
the cells. Stained cell suspensions were washed by PBS and centrifuged 
(1.2×1000rpm, 10 min). 
 
Following centrifuge, supernatant was discarded and stained samples were 
resuspended in PBS and freshly analyzed within 24 h; for later analysis: cells were 
fixed by 1% PFA (30 min, 250 µl/tube), resuspended in PBS (2 ml/tube) and then 
stored at 4°C prior to application. 
 
Flow cytometry analysis: 10.000 events were set up and acquired by the FACS Scan 
(BD PharmingenTM). Data analysis was performed by using CellQuest software (BD 
PharmingenTM). Multicolor was applied for identifying subpopulations of stained cell 
suspensions that were grouped by forward scatter (FSC) and sideward scatter (SSC). 
Percentage of subgroup cells were shown in Dot Plot graphics. 
 
2.2.11 Western blot (WB) 
Sample preparation: Subcutaneous paw tissues of the rat at 96 h post CFA were 
immersed in radioimmunoprecipitation lysis buffer (RIPA) (Table 12) containing 
complete protease inhibitor cocktail (one tablet/10 ml RIPA) and were homogenized 
with sterilized stainless steel beads (5 mm) by Tissuelyser (frequency: 20 Hz, time: 10 
min). Sample supernatant was diluted (5:1) in Laemmli buffer (5×, Table 13) and kept 
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in -20°C before use. 
 
BCA (bicinchoninic acid) protein assay: The protein level of the inflamed paw 
tissue lysate was determined using Pierce BCA protein assay kit. Standards test tube 
protocol and 96-well microplate procedure were used in accordance with the 
manufacturer’s instructions. Albumin standard dilutions were prepared in the range 
from 20 to 2000 µg/ml in RIPA buffer (without complete protease inhibitor) and 
measured in triplicate (25 µl/well). 10-fold diluted samples (in RIPA buffer) were also 
measured in triplicate (25 µl/well). Reagent A and B were mixed (50:1) and used as a 
working reagent (200 µl/well), followed by a thorough mixture for the microplate on 
the shaker (30 s). The plate was covered and incubated at 37°C for 30 min. The plate 
was then cooled down to RT and the absorption at 540 nm was measured using an 
UV/Vis spectrophotometry (Sunrise® Tecan) after incubation. The concentration of 
each sample was calculated referring to the O.D. values that were interacted with the 
values on a linear standard curve. 
 
Western blot: 25 µg of protein of inflamed paw tissue lysate diluted in Laemmli 
buffer was separated on a 10% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE, 50 V for 30 min and then 150 V for 80 min) (Table 14) 
by Volt POWER Supply and then immobilized onto nitrocellulose membranes (15 V, 
90 min). The extracted membranes were blocked at RT for 1 h with 5% nonfat milk in 
Tris-buffered saline with 0.05% Tween20 (TBS-Tween), and the incubation was 
performed at 4°C overnight (with agitation of 50 rpm) with 
mouse-monoclonal-anti-MOR (1:500), rabbit-polyclonal-anti-DOR (1:250) or 
rabbit-polyclonal-anti-KOR (1:1000). Mouse-monoclonal-anti-GAPDH (1:2000) was 
loaded as a control. Following washing with TBS-Tween (3×10 min), the membranes 
were continuously incubated at RT (with agitation of 50 rpm) for 1 h with anti-mouse 
secondary Ab (1:5000) or anti-rabbit secondary Ab (1:3000) conjugated to 
horseradish peroxidase, dissolved in TBS-Tween with 2.5% nonfat milk and 2.5% 
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BSA. Blots were washed repeatedly with TBS-Tween (3×10 min) prior to detection. 
 
Image obtaining and densitometric analysis: Protein bands-loaded membranes were 
visualized using ECL for 1 min and were then immediately exposed to the 
autoradiography camera for 3-10 min. IDV of each protein band was determined. 
Analysis was performed within the same blot. The differences of raw IDV values of 
the target protein and GAPDH were firstly calculated. Then relative IDV values of 
target protein to the average IDV of GAPDH were calculated. The individual relative 
value was normalized to the average value of all samples and further applied for 
statistical analysis. Both scanning and densitometric analyzing were performed using 
FluorChem FC2 MultiImage II system. 
 
Table 12: Recipe of RIPA buffer 
25 mM HEPES, pH 7.6 
2 mM EDTA 
25 mM NaF 
1% SDS ultrapure 
 
Table 13: Recipe of Laemmli buffer 
250 mM Tris, pH 6.8 
2% SDS ultrapure 
10% Glycerol 
1% Beta-Mercaptoethanol 
2 mM EGTA 
1 mM PMSF 
0.2% Bromophenol Blue 
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Table 14: Components of 10% SDS-PAGE 
H2O 
Acrylamide/Bis (30:2) 
3M Tris, pH 8.8 
10% SDS 
10% APS 
TEMED 
 
2.2.12 Rat macrophages harvest and stimulation by CXCL10 
(Release) 
Rat macrophages harvest and isolation: Inflammatory peritoneal rat macrophages 
were harvest and obtained at 96 h post intraperitoneal (i.p.) injection of 3% 
thioglycolate [46]. Rats were intracardially sacrificed by an overdose of potent 
sedative drug T61 (300 l/rat) [47]. Peritoneum lavage was performed (i.p.) with 
EDTA (0.2 M, 100 l) containing PBS (20 ml). Macrophages enriched peritoneal 
fluid was collected and diluted in EDTA/PBS (400 l 0.2 M EDTA in 30 ml PBS) on 
ice. Freshly isolated macrophages suspension was purified by sequential addition of 
0.2% and 1.6% hypotonic NaCl to lyse the debris of red blood cells. Cell suspensions 
were spun down (1.2×1000 rpm, 10 min) and resuspended in PBS. Cell numbers were 
counted 1:20 in Trypan Blue. Following centrifuge (1.2×1000 rpm, 10 min), cells 
were resuspended in HBSS containing the proteinase inhibitors bestatin (40 µg/ml), 
aprotinin (1 µg/ml) and thiorphan (25.33 µg/ml), and concentration of resuspended 
cells was adjusted to 0.5×106 cells/100 l. 
 
Release: Before stimulation, the concentrations of all reagents were adjusted in 
proteinase inhibitor containing-HBSS as diluent. Purified rat macrophages 
co-incubated with selected doses of recombinant rat CXCL10 (0.01, 0.1 and 1 ng) 
were agitated on a shaker (700 rpm, 37°C) following a pre-incubation with 
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cytochalasin B (5 mg/ml) for 5 min [29]. The dose range of CXCL10 was adjusted in 
accordance with behavioral and pilot experiments. HBSS and ionomycin (10 µM) were 
used as a solvent control and a positive control. Supernatants were obtained after 15 
min stimulation. Acquired cellular suspension was centrifuged (4×1000 rpm, 5 min) 
and supernatants were then stored at -20°C until further analysis was conducted by 
ELISA using commercially available kits for rat END detection. 
 
2.3 Experimental design 
Before experiments, all animals were randomly divided to CFA + EA (CFA rats with 
EA treatment), CFA + sham (CFA rats with sham EA treatment) as well as CFA (CFA 
rats without treatment). 
1. Changes of nociceptive threshold were daily measured from day 0 to day 6 
(0-144 h) and paw volume and temperature were simultaneously assessed. 
Antagonists of opioid receptors (NLX, NTI) or Abs against opioid peptides 
(anti-END, -ENK and -DYN) were respectively applied (i.pl.) at 96 h post CFA; 
nociceptive threshold changes were assessed 5 min post injection. 
2. Rat Cytokine Array for 29 cytokines was performed at 96 h CFA to firstly 
discover the positively expressed cytokines/chemokines in the inflamed paw 
by EA treatment, and then ELISA was conducted to quantify the protein level 
of selected cytokines/chemokines from Cytokine Array and to recognize 
targeted cytokine/chemokine. The following RT-PCR experiments were 
performed to detect mRNA level of targeted chemokine CXCL10 by CFA + 
EA treatment in the inflamed paw tissue taken at both 72 and 96 h post CFA. 
Subsequent double immunostaining of the inflamed paw tissue (96 h CFA) for 
macrophages (ED1 or anti-macrophages serum) with either each opioid 
peptide (END, ENK and DYN) or CXCR3 (CXCL10 receptor) were 
performed. 
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3. CFA rats were administered (i.pl.) with CXCL10 (0.2 ng) or CFA + EA rats 
were injected (i.pl.) with the CXCL10 blocking Ab (2g) either at 96 h CFA or 
daily performed (0-4 day, 5 times). Nociceptive thresholds were 
correspondingly assessed. Double immunostaining with 
monocytes/macrophages (ED1) and opioid peptides for inflamed tissue daily 
(0-4 day, 5 times) treated with CXCL10, or the Ab against CXCL10, was 
applied. 
4. Opioid receptor levels were evaluated by WB at 96 h CFA. Opioid peptide 
release (END) from CXCL10 stimulated rat macrophages in vitro was detected 
by ELISA. 
 
2.4 Statistical analysis 
All data were presented as mean  SEM. Multiple measurements at one time point 
between two or more than two groups were analyzed by t-test or one way analysis of 
variance (ANOVA), respectively. Multiple measurements at different time points 
between two or more than two groups were analyzed by two way repeated 
measurements (RM) ANOVA. The Holm-Sidak method was used for one way ANOVA 
and the Student-Newman-Keuls Method was used for two way RM ANOVA. * P < 0.05 
or ** P < 0.01 was regarded as statistically significant (Significance between CFA + EA 
and CFA + sham was represented by $p < 0.05, and significance between CFA + sham 
and CFA was represented by #p < 0.05, showed in Fig. 10 and 11). 
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3. Results 
3.1 Acupoint positioning and needling were modeled by 
computer-based 3D rat model 
As illustrated before, accurate position of acupoint is the premise of achieving “De 
Qi” sensation, however, unclear acupoint location on animals in previous studies 
hampered the reproducible application by subsequent researchers. An anatomically 
accurate skeleton based rat model created by Maya 2012 clearly displayed essential 
acupoint positioning for GB-30 Huantiao in a 3D space. Acupuncture needles were 
inserted bilaterally into the GB-30 Huantiao. Needling angle, depth and relative 
location to bony marks could be distinctly visualized by rotating the model from all 
perspectives, although the visualized perspectives were restricted by two-dimensional 
image shown in Fig. 8. 
 
 
Fig. 8: GB-30 Huantiao needling essential exhibited by computer-based 
three-dimensional (3D) rat model. The needles were inserted perpendicularly into 
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GB-30 Huantiao. [A] Acupoint location and needling on GB-30 Huantiao was 
modeled by 3D computer-based rat model. [B] Distance between bilateral needles 
inserted on GB-30 Huantiao (yellow dots) was approximately 1.5-2 cm from rear 
perspective. [C, D] Needle tips perpendicularly inserted underneath GB-30 Huantiao 
reached nearby tissues of sciatic nerve from side or vertical view (Figure and legend 
were modified from Fig. 1 in [5]). 
 
3.2 Optimal parameter selection for EA by comparison of 
different frequencies 
EA-induced antinociception in the central nervous system (CNS) was validly 
attributed as frequency-dependent (Fig. 1). However, which frequency and treatment 
setting could produce optimal sustained analgesia has not been very well examined. 
Rather than testing multiple parameters and examining their effects on antinociception, 
this thesis initially focused on evaluating the potential different nociceptive effects 
between multiple frequencies, with other pre-established parameters including 
intensity (2-3 mA), pulse width (0.1 ms) and duration (20 min) on acupoint GB-30 
Huantiao according to early researcher [16]. This allowed us to evaluate differences in 
the frequencies (including 10, 2/100, 120 and 100 Hz) and timing of the EA 
application (One EA treatment at 0 h CFA or two EA treatments at both 0 and 24 h 
CFA). The frequencies were selected according to pilot experiments (data not shown). 
Thermal nociceptive thresholds changes (paw withdrawal latency, PWL) were 
assessed. Treatment of 2/100, 120 and 100 Hz displayed distinctive features of 
nociception (Fig. 9B-D) whereas 10 Hz produced a small anti-hyperalgesia effect 
without significance (Fig. 9A). Since the purpose of this study was principally 
concerned with tonic analgesia at a late phase of CFA (72-96 h), it was manifest that 
high frequency 100 Hz (Fig. 9D) and an alternatively changed frequency 2/100 Hz 
(Fig. 9B) showed comparable postponed antinociception at 72 and 96 h CFA, and 
obviously that one treatment of each frequency potentiated the maximal effect 
obtained at 72 h. Due to the mechanisms for high frequency 100 Hz were scantly 
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understood from previously restricted investigations, this frequency was thereby 
selected for following study. Two treatments of 100 Hz further extended the maximal 
effect from 72 to 96 h, which exactly matched the initial assumption (Fig. 9E). 
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Fig. 9: EA produced thermal antinociception was frequency-dependent. EA 
treatments (0.1 ms, 2-3 mA, 20 min) with different frequencies (10, 120, 2/100 or 100 
Hz) on bilaterally GB-30 Huantiao were performed on rats with CFA inflammation. 
[A-D] One EA treatment with selected frequencies was applied. Thermal nociceptive 
thresholds (paw withdrawal latency, PWL) were measured at given time points (0, 2, 
24, 48, 72 and 96 h). [E] Two treatments (0 and 24 h) of 100 Hz EA (0.1 ms, 2-3 mA, 
20 min) were performed. PWL was assessed at same time points. Data were shown as 
mean ± SEM (n = 6 per group, *p < 0.05, CFA + EA versus CFA; two way RM 
ANOVA, Student-Newman-Keuls, n = 6 per group). (Figure and legend were 
modified from Fig. 2 in [5]). 
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3.3 EA produced sustained antinociception and 
anti-inflammation 
Optimal EA settings (two treatments at 0 and 24 h, frequency: 100 Hz, intensity: 2-3 
mA, pulse wide: 0.1 ms, duration: 20 min) was established by thermal nociceptive 
assessment in Fig. 9. The further question was asked whether the same setting could 
also produce comparable mechanical antinociception. To suggest the specificity of 
EA-produced antinociception, sham-EA treatment was applied as an additional 
control. Two treatments of optimal EA settings reversed mechanical (PPT) and 
thermal hyperalgesia (PWL) respectively at different time points (Fig. 10A, B). The 
mechanical antinociception started at 48 h (Fig. 10B), earlier than thermal 
antinociception (Fig. 10A) and sustained until 144 h post CFA (Fig. 10C). There was 
a reversal effect on PPT at 96 h by sham EA treatment compared to the CFA control 
(Fig. 10B). 
 
The anti-inflammatory effect was considered by early researchers to be frequency 
-dependent [48] whereas other researchers provided conflicting information [8]. For 
the purpose of distinguishing the current discrepant conclusions, inflammatory 
indicators including volume and temperature of inflamed paw from either EA, 
sham-EA or CFA treatment were selected and compared to evaluate the inflammation 
elicited by CFA. The daily assessment of changes of paw volume and temperature 
from 0 to 144 h CFA demonstrated that EA could significantly decrease the inflamed 
paw temperature at both 72 and 144 h compared to CFA control, whereas the 
significance between EA and sham-EA occurred only at 72 h (Fig. 11A). Paw volume 
was attenuated by EA in comparison with sham-EA and CFA control at 72 and 144 h 
respectively (Fig. 11B). No difference between sham-EA and CFA control was 
observed at each time point. 
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Fig. 10: Sustained mechanical and thermal antinociception were produced by two 
applications of EA. Optimal EA settings (frequency: 100 Hz, intensity: 2-3 mA, 
pulse wide: 0.1 ms, duration: 20 min) was applied at 0 and 24 h on rat treated (i.pl.) 
with CFA. [A, B] Paw pressure threshold (PPT) and paw withdrawal latency (PWL) 
were daily assessed at 0, 48, 72 and 96 h (n = 6 per group). [C] Changes of PPT were 
measured up to 144 h post CFA (n = 8 per group). Data were shown as mean ± SEM (*p 
< 0.05, CFA + EA versus CFA; $p < 0.05, CFA + EA versus CFA + sham; #p < 0.05, 
CFA + sham versus CFA; two way RM ANOVA, Student-Newman-Keuls). (Figure 
and legend were modified from Fig. 3 in [5]). 
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Fig. 11: EA reduced CFA-evoked paw swelling and increased temperature. Rats 
injected (i.pl.) with CFA received two EA treatments at 0 and 24 h as described before. 
[A] Skin temperature of inflamed plantar was repeatedly assessed (7 times, daily, 0 
to144 h post CFA). [B] Inflamed paw volume was evaluated at same time points. Data 
were shown as mean ± SEM (n = 8 per group, *p < 0.05, CFA + EA versus CFA; $p < 
0.05, CFA + EA versus CFA + sham; two way RM ANOVA, Student-Newman-Keuls). 
(Figure and legend were modified from Fig. 5 in [5]). 
 
3.4 Peripheral endogenous opioids contributed to tonic 
antinociception of EA 
Opioid receptors in past decades were thought to play a role in EA-produced 
analgesia from both clinical and experimental studies majorly via pre-EA application 
of antagonists of opioid receptors [4,11,14,16,49], frequently referring to MOR 
antagonist NLX or Cys2, Tyr3, Orn5, Pen7-amide (CTOP), DOR antagonist NTI as 
well as KOR antagonist nor-binaltorphimine (Nor-BNI). 
 
In a previous study, we illustrated that MOR and DOR as well as opioid peptide END 
and ENK were involved in tonic analgesia at an early phase (2 h) of CFA by 
post-CFA administration of NLX, NTI or Abs of each opioid peptide [29] (Fig. 5). In 
order to explore whether opioid receptor MOR and DOR mediated tonic 
antinociception produced by current EA settings at a late phase (96 h) of CFA, 
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optimal doses of NLX (0.56 ng) and NTI (25 µg), determined by pilot experiments 
(Fig. 12A, B) and early studies [29] were injected (i.pl.) and distinctly showed 
reversal of EA-induced antinociception at 96 h CFA (Fig. 12C, D). Of note, the 
mechanical threshold of sham-EA was not affected by an identical dose of NLX (Fig. 
12C). 
 
Depending on the frequency used, opioid peptides were released from perfusate of 
subarachnoid space of spinal cord by EA [15] (Fig. 1). To understand the role of 
peripheral opioid peptides in tonic antinociceptive effects at high frequency (100 Hz) 
EA, optimal doses of blocking Abs against opioid peptides (anti-END, -ENK, -DYN) 
determined from preliminary experiments and the study mentioned above [29] were 
post-EA administered at 96 h CFA respectively. Increased mechanical hyperalgesic 
thresholds of EA were suppressed by each performance of the Abs (Fig. 13D, E, G) 
whereas thermal hyperalgesic thresholds of EA were only inhibited by anti-END and 
-ENK (Fig. 13A, B) 5 min post injection. Simultaneous injection of anti-END and 
anti-ENK Abs did not produce better effects than single injections of each Ab (Fig. 
13F). 
 
Depending on the comparison between all mechanical and thermal hyperalgesic tests, 
we discovered: 
1. Mechanical antinociception of EA was evidently addressed earlier (starting 
from 48 h CFA (Fig. 10B) and in a more sustained manner (up to 144 h CFA, 
Fig. 10C) than thermal antinociception (Fig. 10A) which is also partially in line 
with former research demonstrating better mechanical than thermal 
hyperalgesic suppression by EA [50]. 
2. There was extensive involvement of opioid peptides (END, ENK and DYN) in 
mechanical anti-hyperalgesia (Fig. 13D-G) whereas only END and ENK were 
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involved in thermal anti-hyperalgesia (Fig. 13A-C). 
Additionally, the mechanism of mechanical hyperalgesia was distinct from the thermal 
hyperalgesia, as reported by previous studies, therefore only mechanical nociceptive 
measurement was applied in subsequent investigations. 
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Fig. 12: Antagonists of MOR (naloxone, NLX) and DOR (naltrindole, NTI) 
reversed EA-induced mechanical antinociception at late phase (96 h) of CFA. 
Rats with CFA inflammation were treated with two EA treatments (at 0 and 24 h, 100 
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Hz, 2-3 mA, 0.1 ms, 20 min) or sham-EA. [A, B] Dose-response experiments were 
designed to establish the optimal dose of the opioid receptor antagonists, Paw pressure 
threshold (PPT) changes were assessed following administration (i.pl.) of selected 
doses of NLX (0.28, 0.56 and 1.12 ng) and NTI (25, 50 and 100 µg) in EA treated rats 
were measured before (baseline: BL) and 5 min after injection (Treated) (n = 3-5 per 
group). [C, D] Optimal doses of NLX (0.56 ng) and NTI (25 µg) were further applied 
(i.pl.) on EA or sham-EA treated rats, PPT were measured before (BL) and 5 min 
(Treated) post injection. Identical amount of solvent (saline) was administered (i.pl.) as 
control. Pain thresholds of CFA rats (CFA) at 96 h were only presented for comparison 
but not for statistical analysis (n = 6 per group). Data were shown as mean ± SEM (*p < 
0.05, CFA + EA + NLX/NTI versus CFA + EA + saline, or, CFA + EA + NLX/NTI 
versus CFA + sham + NLX versus CFA + EA + saline; two way RM ANOVA, 
Student-Newman-Keuls). (Figure and legend were modified from [5]). 
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Fig. 13: EA attenuated CFA-induced hyperalgesia via peripheral opioid peptides 
at late stage (96 h) of CFA. Anti-END (2 µg [A, D]), anti-ENK (1.25 µg [B, E]), 
combination of anti-END and –ENK [F] or anti-DYN (1 µg [C, G]) was administered 
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(i.pl.) at 96 h CFA on rats with two EA treatments (at 0 and 24 h, 100 Hz, 0.1 ms, 20 
min, 2-3 mA). Control animals were injected with identical doses of rabbit IgG or 
received CFA without EA treatment. Paw withdrawal latency [A-C] or paw pressure 
threshold [D-G] was determined before (BL: baseline) and 5 min after injection 
(Treated). CFA without EA treatment (CFA) was included as basal threshold of 
inflamed paw for comparison but not for statistical analysis. Data were shown as mean 
± SEM (n = 6 per group, *p < 0.05, **p < 0.01, CFA + EA + anti-END/ENK/DYN 
versus CFA + EA + IgG; two way RM ANOVA, Student-Newman-Keuls). (Figure and 
legend were modified from [51]). 
 
3.5 EA selectively regulated expressions of certain 
cytokines/chemokines 
Aiming to find out whether local cytokines at inflammation site were modulated by EA 
at late phase (96 h) of CFA, relative levels of a total of 29 cytokines in inflamed or 
non-inflamed paw tissue from rats treated with CFA or CFA + EA were evaluated by 
Cytokine Array (Fig. 14). 
 
In accordance with Cytokine Array, protein levels of seven cytokines/chemokines 
(CXCL10, IFN-gamma, TNF-alpha, IL-1alpha, IL-1beta, IL-4, IL-13) which displayed 
promising signals were further quantified by ELISA. Pro-inflammatory cytokines 
including TNF-alpha (Fig. 15A) and IL-1beta (Fig. 15C) were apparently 
downregulated by EA whereas IL-1alpha (Fig. 15B) was not affected. The 
anti-inflammatory cytokine IL-13 (Fig. 15E) was distinctly upregulated by EA 
whereas IL-4 (Fig. 15D) was barely regulated. Intriguingly, pro-inflammatory 
cytokine IFN-gamma was not commonly upregulated (Fig. 15F). 
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Fig. 14: Partial restoration of local cytokine profile by EA at late phase (96 h) of 
CFA. At 96 h CFA, rats with CFA inflammation were randomly treated with/without 
EA and grouped as CFA and CFA + EA. Inflamed and non-inflamed (contralateral) 
paw tissue were used for Cytokine Array. Local 29 cytokines signals (values were 
displayed as integrated density value (IDV) of each cytokine relative to positive 
control) were detected by Cytokine Array and selectively exhibited with 4 chemokines 
(CXCL1, CXCL2, CXCL3 and CXCL10) and 11 cytokines including IFN-gamma, 
TNF-alpha, IL-1alpha. IL-1beta, IL-2, IL-3, IL-6, IL-4, IL-10, IL-13, IL-17. Data were 
presented as mean ± SEM in all groups; non-inflamed (contralateral) paw tissue was 
included only for comparison but not for statistical analysis. No difference was 
observed between EA treatment and CFA control for each cytokine/chemokine (n = 
5-6 per group, CFA + EA versus CFA, t-test). 
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Fig. 15: EA alternatively regulated expressions of certain cytokines/chemokines 
at late phase (96 h) of CFA. Rats with CFA inflammation were randomly treated 
with/without EA and grouped as CFA and CFA + EA. At 96 h CFA, protein levels 
(pg/ml) of cytokines including IFN-gamma, TNF-alpha, IL-1alpha, IL-1beta, IL-4, 
IL-13 in inflamed paw were quantified by ELISA as a result of comparatively 
promising expression from Cytokine Array in Fig. 14. Data were shown as mean ± 
SEM (n = 5-6 per group, CFA + EA versus CFA, t-test). (Figure and legend were 
modified from [51]). 
 
3.6 Upregulation of CXCL10 and CXCR3-expressing 
macrophages were associated with EA 
IFN-gamma inducible chemokine CXCL10 was initially recognized as 
chemoattractant for T cells and monocytes [52]. Upregulation of IFN-gamma by EA 
potentiated subsequent experiments to concentrate on chemokine CXCL10, due to the 
former studies on antinociceptive property of CXC-chemokines in relieving CFA 
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inflammatory pain [27] (Fig. 4). EA remarkably promoted both the protein and mRNA 
level of CXCL10 (Fig. 16A, B). Since no change was seen on CXCL10 protein level 
in sham-treated animals (Fig. 16A), the sham-EA group was excluded from further 
mRNA analysis (Fig. 16B). 
 
Peripheral opioid peptides secretion at the early stage of CFA (2 h) was mainly 
attributed to infiltrating neutrophils whereas inflammatory monocytes/macrophages (> 
60%) were mainly the reason for opioid peptide secretion at the late phase (48-96 h) of 
CFA. At late phase (96 h) of CFA, only a small subpopulation of infiltrating T cells (< 
5%) was identified, confirmed early conclusions [26] (Fig. 17). 
 
Known from chemokine receptor CXCR3-unique receptor of CXCL10 [53], as well as 
the increased transcription and translation level of CXCL10 by EA in Fig. 16, the 
receptor availability for CXCL10 was evaluated by double staining for CXCR3 and 
macrophage in inflamed tissue. Co-expression content was analyzed. CXCR3 
expression was observed on the vast majority of infiltrating macrophages (Fig. 18A). 
As expected, EA markedly enhanced the amount of CXCR3+ expressing macrophages 
in all marked cells in comparison to CFA control (Fig. 18B). 
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Fig. 16: Upregulation of CXCL10 by EA at late phase (72-96 h) of CFA. [A] All 
rats with CFA inflammation randomly received treatment with EA or sham-EA, and 
grouped as (CFA + EA), (CFA + sham) and CFA. At 96 h, ELISA was applied to 
quantify the level (pg/ml) of CXCL10 in subcutaneous paw tissue from each group; [B] 
mRNA level was detected by RT-PCR (tissue taken from 72 and 96 h), non-inflamed 
paw (contralateral) was only showing as a negative control instead of applying for 
statistical analysis. Data were shown as mean ± SEM (For ELISA: n = 6 per group, *p < 
0.05, CFA + EA versus CFA + sham versus CFA, one way ANOVA, Holm-Sidak 
method; For RT-PCR: n = 6 per group, *p < 0.05, CFA + EA versus CFA; t-test). 
(Figure and legend were modified from [51]). 
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Fig. 17: ED1 positive tissue monocytes/macrophages constituted the major 
subtype of leukocytes at late phase (96 h) of CFA. Cells suspensions from 
subcutaneous non-inflamed [A] or inflamed [B] paw tissue were first stained. Dot Plot 
graphics showed the gate R1 on CD45-PE-Cy5 marked hematopoietic cells ratio in 
non-inflamed (0.88%) or inflammatory paw tissue (50.27%) (X-axis: forward scatter 
(FSC), Y-axis: CD45-PE-Cy5). CD45+ cells were further stained for ED1-FITC 
identifying monocytes/macrophages [C] or CD3-FITC recognizing T cells [D]. Dot 
Plot graphics showed double stained hematopoietic cells gated on R2 for CD45+ED1+ 
(64.53%) or CD45+CD3+ (1.43%) cell group (X-axis: ED1/CD3-FITC, Y-axis: PE). 
Only representative samples are shown (n=4-5 for each staining). 
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Fig. 18: Upregulation of CXCR3+ macrophages in inflamed paw tissue by EA at 
late phase (96 h) of CFA. [A] At 96 h CFA, double staining on slices from inflamed 
tissue treated with/without EA was performed with rabbit anti-macrophage antiserum 
(red), mouse anti-CXCR3 (green). DAPI (blue) were stained to recognize cell nuclei. 
White arrows were pointing at double positive cells (Scale bar: 50 µm). [B] 
Quantification analysis displayed the ratio (%) for overlapping content of CXCR3 
with macrophages in total amount of macrophages marked by antiserum. All data were 
presented as mean ± SEM (n = 3 per group, *p < 0.05, CFA + EA versus CFA; t-test). 
(Figure and legend were modified from [51]). 
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3.7 EA increased opioid peptides expression on recruited 
monocytes/macrophages 
Not only central (Fig. 1) but also peripheral opioid peptides [17] contributed to EA 
induced antinociception. EA has been indicated to be responsible for robust 
upregulation of END expression on ED1 marked infiltrating monocytes/macrophages 
in inflamed paw at 6 days post CFA [3]. Since all three opioid peptides have been 
involved in EA-triggered antinociception (Fig. 13), we intended to figure out whether 
and how opioid peptide expression on monocytes/macrophages was regulated by 
current EA settings in the inflamed paw. Double staining on monocytes/macrophages 
(ED1 marked) with each opioid peptide (Abs against END, ENK and DYN) was 
performed (Fig. 19A-C). Quantification analysis showed EA increased expression 
ratio (approximately 75% for ENK, 65% for END and 60% for DYN) of all three 
opioid peptides on ED1 positive monocytes/macrophages compared to CFA rats, 
whilst no change was obtained between sham-EA and CFA treatment (Fig. 19D). 
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Fig. 19: EA promoted the opioid peptide expression on monocytes/macrophages 
at late phase (96 h) of CFA. All rats with CFA inflammation were randomly treated 
with EA or sham-EA, and grouped to (CFA), (CFA + EA), (CFA + sham). [A-C] 
Double immune staining with mouse anti-ED1 (CD68, identifying 
monocytes/macrophages, green) and rabbit anti-END/-ENK/-DYN respectively (All 
marked as red) was performed. Nuclei of cells were marked with DAPI (Blue). White 
arrows were pointing at double positive cells (Scale bar: 50 µm). [D] Quantification 
analysis displayed the ratio (%) of double positive ED1 marked 
monocytes/macrophages in total amount of ED1+ cells. Data were shown as mean ± 
SEM (n = 3 per group, *p < 0.05, one way ANOVA, CFA + EA versus CFA + sham 
versus CFA, Holm-Sidak method) (Figure and legend were modified from [51]). 
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3.8 CXCL10 reversed CFA-induced mechanical 
hyperalgesia via peripheral opioid peptides 
To our knowledge, certain chemokines were recognized as peripheral 
opioid-dependent antinociceptive in CFA induced inflammatory pain. At 2 h CFA, 
local administration (i.pl.) of chemokine CXCL2/3 dose-dependently attenuated 
mechanical hyperalgesia which was associated with promoted migration of 
neutrophils leading to opioid peptide (END and ENK) release regulated by 
intracellular Ca2+ level [27]. 
 
Since chemokine CXCL10 was markedly upregulated by CFA + EA treatment in 
former experiments (Fig. 16), we then speculated that CXCL10 and CXCL2/3 might 
share common mechanisms. Mechanical threshold changes were assessed in pilot 
experiments after single local administration (i.pl.) of different doses of rat 
recombinant CXCL10 (0.2, 2, 20 and 200 ng; data not shown). 0.2 ng CXCL10 better 
suppressed mechanical hyperalgesia than other doses and was chosen for subsequent 
studies. Time-course experiment for single application (i.pl.) of 0.2 ng CXCL10 at 96 
h displayed persistent anti-hyperalgesic effect until 3 h post injection (Fig. 20A) and 
daily application of an identical dose of CXCL10 fundamentally reversed mechanical 
pain threshold of CFA-elicited hyperalgesia (Fig. 20B). To further understand the 
mechanism, changes of nociceptive thresholds were evaluated following concomitant 
administration (i.pl.) of repeated CXCL10 (daily performance, from 0-4 day, 5 times) 
with each opioid peptide Ab (anti-END, -ENK, -DYN; acute performance, at 96 h). 
Complete reversed thresholds at 5 and 15 min post injection by anti-END, -ENK or 
-DYN suggested a peripheral opioid peptide-dependent feature of CXCL10 induced 
antinociception (Fig. 20C-E). 
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Fig. 20: Sustained mechanical antinociception elicited by CXCL10 was opioid 
peptide–dependent. Rats injected (i.pl.) with CFA received acute (at 96 h) or repeated 
(5 times, daily from 0 to 96 h) application with CXCL10 (0.2 ng) or solvent control. [A] 
0.2 ng CXCL10 was i.pl. applied at 96 h CFA and paw pressure threshold (PPT) were 
was evaluated before (BL) and 5, 15, 45 min and 2, 3, 24 h after injection. [B] 0.2 ng 
CXCL10 was daily applied (i.pl.) and changes of PPT were daily determined at 0, 24, 
48, 72 and 96 h before each injection. Data were shown as mean ± SEM (n = 6 per 
group, *p < 0.05, **p < 0.01, CFA + CXCL10 versus CFA + solvent; two way RM 
ANOVA, Student-Newman-Keuls). [C-E] At 96 h CFA, rabbit anti-END (2 µg), -ENK 
(1.25 µg) or -DYN (1 µg) was respectively administered (i.pl.) on rats with daily 
treatment of CXCL10 (0.2 ng). Changes of PPT were assessed until 45 min post 
injection. Rabbit IgG was applied (i.pl.) as control. Data were presented as mean ± 
SEM (n = 6 per group, *p < 0.05, **p < 0.01, CFA + CXCL10 + anti-END/ENK/DYN 
versus CFA + CXCL10 + IgG; two way RM ANOVA, Student-Newman-Keuls) 
(Figure and legend were modified from [51]). 
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3.9 CXCL10 enhanced opioid peptides expression on 
accumulated monocytes/macrophages in vivo instead of 
triggering opioid peptide release in vitro 
Likewise, for the question raised whether the same mechanism accounts for this 
antinociceptive action of CXCL10, we performed identical staining with ED1 marked 
monocytes/macrophages and opioid peptides (END/ENK/DYN) respectively for the 
inflamed paw repeatedly treated with CXCL10. The expression of three opioid 
peptides on ED1+ monocytes/macrophages was extensively enriched in CXCL10 
treated tissue compared to solvent control treatment (Fig. 21A-C). CXCL10 increased 
the expression content of opioid peptides on ED1+ monocytes/macrophages to 72% 
(ENK), 63% (END) and 55% (DYN) (Fig. 21D). 
 
In view of the opioid-dependent antinociceptive effect of CXCL10 on rats, we further 
hypothesized CXCL10 might stimulate opioid peptide release from inflammatory rat 
macrophages in vitro. Thus far, incubation of human CD14+ monocytes and rat 
macrophages with ionomycin (10 m) led to a significant release of END [29] 
theoretically due to elevated calcium intracellular level [54]. Ionomycin was thereby 
incubated as positive control in the present study. Isolated peritoneal rat macrophages 
were obtained 96 h following application (i.p.) of 3% thioglycolate. Three doses (1, 
0.1 and 0.01 ng) of recombinant rat CXCL10 were chosen and 15 min was selected 
for incubation in accordance with preliminary experiments (data not shown). 
Short-term incubation (15 min) time was selected due to the optimal effect in pilot 
experiments in comparison with longer incubation times (60, 120 min and 24 h) (data 
not shown). Incubation of rat macrophages with ionomycin (10 m) led to a 
remarkable END secretion whereas no difference was observed between each dose of 
CXCL10 and solvent control HBSS (Fig. 22). 
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Fig. 21: Increased opioid peptide-expression on monocytes/macrophages by 
repeated CXCL10 injection. Rats with CFA inflammation were repeatedly 
administered (i.pl., 5 times, daily from 0-96 h) with CXCL10 or control solution. 
Slices from inflamed paw tissue sections were used for immune staining. [A-C] At 96 
h CFA, specific section of paw tissue was double stained with a mouse anti-ED1 
(CD68, recognizing monocytes/macrophages, green) and with rabbit anti-rat END, 
-ENK or -DYN Abs (red) and subsequently with DAPI (blue). White arrows were 
pointing at double positive cells (Scale bar: 50 µm). [D] Quantification analysis 
displayed the ratio (%) of double positive ED1 marked monocytes/macrophages in 
total amount of ED1+ cells. Data were shown as mean ± SEM (n = 3 per group, *p < 
0.05, CFA + CXCL10 versus CFA + solvent; t-test) (Figure and legend were modified 
from [51]). 
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Fig. 22: CXCL10 could not trigger opioid peptide release from rat macrophages 
in vitro. Rat inflammatory peritoneal macrophages were isolated at 96 h following 
administration (i.p.) of 3% thioglycolate and then incubated with selected doses of 
CXCL10 (from 0.01 to 1 ng) for 15 min. HBSS buffer (HBSS) and ionomycin (10 µM) 
were used as control and positive control respectively. Beta-END (pg/1×106 cells) was 
quantified by ELISA from the stimulated cell suspension. Data were presented as 
means ± SEM. (n = 4-20, *p<0.05, one way ANOVA, Holm-Sidak method). 
 
3.10 Blockage of CXCL10 impaired EA-induce 
antinociception and downregulated opioid peptide 
expression on monocytes/macrophages 
Known from opioid peptide mediated antinociception of EA, we further asked whether 
an inhibitor of CXCL10 could dampen EA elicited antinociception. Anti-CXCL10 Ab 
was administered (i.pl.) on EA treated rats at 96 h post CFA. Antinociception induced 
by EA was time- and dose-dependently reversed by single i.pl. injection of 2 g 
anti-CXCL10 (Fig. 23A). Multiple applications of an identical dose of anti-CXCL10 
at daily time points completely reversed the pain threshold baseline of EA at 48 h and 
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reached the maximal effect at 96 h (Fig. 23B). The optimal dose 2 g was selected from 
preliminary dose-response (2, 20 and 200 g) experiments (data not shown). 
 
Since repeated treatment of CXCL10 could promote expression of opioid peptides, the 
hypothesis was furthered by whether suppressant of CXCL10 would abolish the 
expression of opioid peptide enhanced by EA. In comparison to rabbit IgG control, 
repeated treatments of anti-CXCL10 blocking Ab markedly lowered the content of 
ED1+ monocytes/macrophages co-expressing the opioid peptides END, ENK and DYN 
(Fig. 24A-C). EA decreased the ratio of opioid peptides expression on ED1 positive 
monocytes/macrophages to 53% (END), 43% (ENK) and 44% (DYN) (Fig. 24D). 
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Fig. 23: Anti-CXCL10 blocking Ab dose- and time-dependently inhibited EA 
produced antinociception. [A] Optimal dose of anti-CXCL10 (2g) chosen from 
preliminary experiments was i.pl. administered on EA treated rats at 96 h post CFA. 
Paw pressure threshold (PPT) was determined before (BL) and 5, 15, 45 min and 2, 3, 
24 h post injection. [B] Changes of PPT were also daily accessed before repeated 
injection (i.pl.) of 2 g anti-CXCL10 at 0, 24, 48, 72, 96 h. All data were presented as 
mean ± SEM (n = 6 per group, *p < 0.05, **p < 0.01, CFA + EA + 2 g anti-CXCL10 
versus CFA + EA + IgG; two way RM ANOVA, Student-Newman-Keuls) (Figure and 
legend were modified from [51]). 
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Fig. 24: Inhibitor of CXCL10 suppressed expression of opioid peptides on 
monocytes/macrophages. Rats with CFA inflammation and treated by EA were 
repeatedly administered (i.pl., 5 times, daily from 0-96 h) with anti-CXCL10 Ab or 
IgG control solution. Slices from inflamed paw tissue sections were used for immune 
staining. [A-C] Double staining was performed with mouse anti-ED1 (CD68, 
recognizing monocytes/macrophages, green) and rabbit anti-END, anti-ENK or 
anti-DYN Abs respectively (red). DAPI (blue) was used to recognize cell nuclei. White 
arrows were pointing at double positive cells (Scale bar: 50 µm). [D] Quantification 
analysis displayed the ratio (%) of double positive ED1 marked 
monocytes/macrophages in total amount of ED1+ cells. Data were presented as mean ± 
SEM (n = 3 per group, *p < 0.05, CFA + EA + anti-CXCL10 versus CFA + EA + IgG; 
t-test) (Figure and legend were modified from [51]). 
 
3.11 Expression of opioid receptors was not altered by EA 
Peripheral analgesia is not only determined on the synthesis and expression of opioid 
peptides on immune cells, but also determined by the amount of opioid receptors 
produced transporting from dorsal root ganglion to nociceptive neurons on nerve 
terminals [55-57]. In the presented data, the protein level of opioid receptors in EA or 
CFA treated inflamed paw was dramatically upregulated in comparison to 
non-inflamed paw (contralateral) which was in complete accordance with previous 
results. As in the previous study we announced opioid receptor antagonist NLX and 
NTI could reverse EA evoked antinociception at 96 h [5], we therefore further 
questioned whether expression levels of opioid receptors in paw tissue were changed 
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by EA. From the presented data, protein levels of DOR and KOR detected by 
immunoblotting were not apparently affected by EA (Fig. 25) in comparison to CFA 
control. Due to the cross-reactivity of second Ab (anti-mouse Ab, GE Healthcare) for 
MOR reported from our laboratory, data from MOR was excluded. 
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Fig. 25: Expression of opioid receptors at inflammation site was not affected by 
EA at late phase (96 h) of CFA. [A] Protein level of DOR and KOR in inflamed or 
non-inflamed paw tissue was evaluated by WB. [B] IDV values normalized to GAPDH 
were calculated within one blot. Protein levels of two receptors were upregulated in 
CFA + EA or CFA treated inflamed paw in comparison to non-inflamed paw 
(contralateral). No difference was seen between CFA + EA and CFA control (n = 6 
per group, *p < 0.05, CFA + EA versus CFA versus contralateral, one way ANOVA, 
Holm-Sidak method). 
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4. Discussion 
In this thesis, a standard EA treatment was established by modeling a 3D visualized 
image on fully free-moving rats with CFA-induced hind paw inflammatory pain. This 
thesis has furthered current understanding of electroacupuncture evoked analgesia 
with: 
1. Two treatments (at 0 and 24 h post CFA) of optimal EA parameters 
(frequency: 100 Hz, intensity: 2-3 mA, pulse wide: 0.1 ms, duration: 20 min) 
on bilateral acupoints GB-30 Huantiao produced sustained thermal and 
mechanical antinociception. 
2. Tonic antinociception produced by EA at a late phase (96 h) of CFA was 
mediated by peripheral opioid receptors and peptides. 
3. Regulation of certain pro- and anti-inflammatory cytokines could arguably 
illustrate anti-inflammatory effects of EA. 
4. Enhanced expression of CXCR3 and opioid peptides on macrophages in 
inflamed paw might be associated with EA induced antinociception, but the 
level of opioid receptors in inflamed paw were unchanged. 
5. Upregulation of chemokine CXCL10 by EA may validly account for EA 
induced antinociception in an opioid peptide-dependent manner. 
 
4.1 3D modeled acupuncture needling and EA treatment on 
conscious fully free-moving rats 
According to TCM theory, the meridian systems theoretically existed in all biological 
organisms. However these meridian systems were thought to be restricted by diverse 
size and anatomical structures in non-human organisms, meaning that not all the 
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acupoints on humans could be successfully projected onto other species. Current 
obscure descriptions of acupoint locations on animals urged us to instigate a clear 
approach to better clarify the positioning and needling on the selected acupoint GB-30 
Huantiao for this study and more importantly to pave a way for future reproducible 
research. Computer-developed 3D modeling is one of the useful tools used to describe 
intricate anatomical structures in a 3D space which is much more vivid than 2D 
presentations. 3D modeling is therefore broadly applied in medical research [58-60]. 
On the basis of the anatomical features of Wistar rats, a computer-based 3D rat 
skeleton model highlighting the bony symbols and needling approach on GB-30 
Huantiao was set up (Fig. 8). However, it is worth noting that the 3D model could 
only provide a guidance for understanding the theoretical essentials of acupoint 
location as well as needling patterns, and the technical gist of accurate performance 
on experimental animals required apperception and considerable practice from 
experimenters. 
 
In TCM theory, “Qi” stands for a beam of energy that circulates in meridians. 
Meridians refer to routes that transport “Qi” and blood, regulate “Yin” and “Yang”, 
connect Zang-Fu organs and associate the upper and lower, and exterior and interior, 
of the body [1]. “Qi” sensation is a frequently discussed theme in TCM as well as in 
acupuncture. Needle insertion will unavoidably evoke a needle sensation that is 
influenced by a number of factors. Nevertheless, an optimal effect can only be 
achieved when “Qi” arrives simultaneously by means of appropriate needling 
manipulations, the so-called “De Qi” sensation. The feeling of “De Qi” can be vividly 
characterized as soreness, numbness, heaviness, distension and aching which can be 
felt by both the patient and practitioner. Unfortunately, “De Qi” sensations from 
acupuncture can of course hardly be well expressed by animals, and in addition an 
invasive needling approach easily evokes a stressful response in terms of 
uncooperative behaviors. Stress-induced analgesia was therefore deemed as a 
contributing reason that accounted for acupuncture-produced analgesia [13]. 
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Anesthetics or restrainers were therefore commonly applied on animals during 
acupuncture for the purpose of relieving the suffering and preventing the bias from 
stress-induced antinociception [20-22] (Fig. 3). Nevertheless, anesthetics or restrainers 
might potentially interfere with molecular signaling processing and/or biological or 
psychological conditions. Because the ’De Qi’ sensation elicited by stimulation of the 
deep tissue underneath the acupoint is the pivotal premise for patients achieving the 
optimal effect of AA [4], an intact sensory system in local tissue was critical. 
Interestingly, EA treatment on conscious rats in a semi-free plastic restrainer was 
shown by other researchers to cause little stress to rats [3,16] (Fig. 2). Nevertheless, 
semi-free restrainers are still less optimal and also not in line with animal welfare 
principles. As a matter of fact, EA treatment on fully free-moving rats has been 
successfully trialed by previous investigator [61]. Therefore, we instituted EA 
treatment on a fully conscious rat allowed free mobility precluding any anesthesia or 
restrainer. 
 
4.2 Characteristics of acupuncture-induced analgesic and 
anti-inflammatory mechanisms 
4.2.1 Characteristics of endogenous opioids associated analgesic 
mechanisms in AA 
Involvement of central opioid peptides and receptors in acupuncture analgesia has been 
intensively addressed [3,4,14-17,19,62,63]. Initial studies indicated 
frequency-determined central opioid-related AA by radioimmunoassay assessment of 
perfusate of the subarachnoid space of the spinal cord and further manifested that low 
frequency (2 Hz) EA potentiated the release of ENK, END and endomorphin (EM), 
while that of high frequency (100 Hz) selectively increased the release of DYN. An 
alternatively changed frequency of 2/100 Hz could elicit a simultaneous release of all 
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phenotypes of the four opioid peptides, leading to an optimal therapeutic action [15]. It 
was also demonstrated that extensive opioid receptors (MOR, DOR and KOR) 
mediated 10 Hz EA-induced antinociception in the central level [49]. Subsequent 
investigations extended this knowledge by identifying the involvement of peripheral 
opioid receptors and peptides in EA-triggered antinociception in different pain models 
[17-19]. Our initial study revealed involvement of peripheral opioid peptide receptors 
in CFA induced inflammatory pain as well as in EA-induced antinociception [5], 
although the expression levels of the opioid receptors were not affected by EA 
treatment (Fig. 25). Consistent with a recent study expounding repeated low 
frequency (2 Hz) EA treatment dramatically upregulated opioid peptide END 
expression on ED1 labeled monocytes/macrophages [3]. This thesis expanded this 
conclusion that two treatments of high frequency (100 Hz) EA promoted the 
expressive content of extensive opioid peptide (END, ENK and DYN) expression on 
ED1 positive monocytes/macrophages (Fig. 19). T cells constituted only a negligible 
rate (< 5%) among the total number of CD45 marked hematopoietic cells at 96 h CFA 
inflamed paw (Fig. 17D), validly supporting earlier investigations [26,64]. 
 
Corresponding to previous studies, peripheral opioid peptides mediated analgesia at an 
early stage (0-6 h) of CFA. This was due to the release of opioid peptides from 
neutrophils while monocytes/macrophages are considered as mainly responsible for the 
late phase (96 h) of CFA inflammation [26,45,65]. In earlier investigations, it was 
discovered that opioid peptide release did not only occur after cold water swim stress or 
exogenous stimulations but also was present under basal conditions depending on 
bacterial products via formyl peptide receptor stimulation [29]. The present study 
furthered current knowledge by illuminating the involvement of local opioid receptors 
and peptides on tonic antinociception of EA via post-EA application of opioid 
receptor antagonists (Fig. 12) or opioid peptide Abs (Fig. 13). 
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4.2.2 Endogenous cytokines-related anti-inflammatory properties of 
acupuncture 
The effects of acupuncture against inflammation have been well documented 
[8-10,48,66]. It was suggested that lower frequencies (2 or 10 Hz) rather than higher 
frequencies EA (100 Hz) could attenuate inflammatory swelling, despite the fact that 
both patterns could produce comparable antinociceptive effects [48,66]. However in 
present study, elevated temperature and volume of the inflamed paws were distinctly 
depressed by high frequency EA (100 Hz) at 72 and 144 h post CFA (Fig. 11), although 
the anti-inflammatory effects of EA seemed less pronounced than the antinociceptive 
effects (Fig. 10). This might suggest that the anti-inflammatory action of EA was not so 
much determined by frequency but rather the appropriate parameter settings and 
individual performance was more relevant. 
 
Cytokines were for a long time suggested to be involved in acupuncture elicited effects 
including anti-inflammatory action. The alleviated inflammation related cytokine 
changed by acupuncture has been extensively addressed [10,22,48,67]. Cumulative 
studies put forward the distinctive role of modulating cytokine expression by 
acupuncture, which was suggested to be balancing the T helper 1(Th1)-and T helper 2 
(Th2) subtype immune cells-released cytokines [67-70]. In the presented data, EA 
significantly attenuated the level of pro-inflammatory molecule TNF-alpha and 
IL-1beta (Fig. 15A, C), which was in line with the previous research [10]. In addition, 
increased Th1 cell type cytokine IFN-gamma (Fig. 15F) as well as Th2 cytokines IL-13 
(Fig. 15E) might also suggest interacted signaling of a subtype of cytokines, including 
at least Th1 and 2, is involved in the mechanism scheme. 
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4.2.3 Potential placebo effect underlying verum acupuncture requires 
sham acupuncture control 
Several lines of evidence from randomized controlled trials proposed the specific 
curative effect of verum acupuncture in comparison to sham acupuncture in pain 
management [71,72]. The existing studies however have also advocated the same 
superior effect produced by sham acupuncture, implying potential placebo effects 
behind verum acupuncture [73-76]. The question remains in clinical research which 
sham control would be optimal to exclude the bias from acupuncture skepticism 
[77-81]. Of note, the analgesic effect of sham treatment was overwhelmingly reported 
in patients. Analogical cases from animals were scantly mentioned, which allowed the 
author to suspect the possible involvement of technical deviations between different 
practitioners as well as the psychological factors among the patients [82-84]. In the 
present study, invasive sham-EA elicited slight antinociception at given time points 
(96 h CFA) (Fig. 10), this may again suggest the described “minimal needling” of 
sham-EA was not sufficiently minimal. However, the increased mechanical threshold 
of sham-EA treated rats was barely affected by administration of an identical dose of 
NLX (Fig. 12C), this would be an implication that the sham treatment triggered tonic 
anti-hyperalgesic effect might not depend on peripheral opioid receptors, partially in 
concordance with the distinct activation property of MOR in verum and sham 
acupuncture in earlier publication [85]. 
 
4.3 Tangled interaction between IFN-gamma and CXCL10 
in immune responses and potential association in 
attenuating inflammatory pain by EA 
The IFNs family was classified into type I and type II according to receptor specificity 
and sequence homology. IFN-gamma is so far the only known member of type II IFN, 
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which was believed to be produced by lymphocytes, T cells, NK cells, 
monocytes/macrophages, and dendritic cells [86-88]. Both types of IFN possess 
antiviral and immune-modulatory activities in early infectious stage [89-91]. 
Augmenting the immune system response to increased immune system sensitivity and 
in response to pathogens is suggested to be an important function of IFN-gamma during 
infection, one of the key means by which it modulates and trafficks specific immune 
cells to sites of inflammation through upregulating expression of adhesion molecules 
and chemokines [92]. 
 
Chemokines are a family of cytokines that play an important role in the recruitment of 
leukocytes to inflammatory sites. They have been subdivided into families on the basis 
of the relative position of their cysteine residue. The subtype alpha-chemokines 
(CXC-chemokines) which generally contain CXCL8 (interleukin-8, IL-8), CXCL10, 
and CXCL9 (monokine induced by interferon-gamma, MIG) are mainly chemotactic 
for neutrophils and T lymphocytes whereas the beta-chemokines (C-C-chemokines) 
including CCL2 (monocyte chemoattractant protein-1, MCP-1), CCL7 (monocyte 
chemoattractant protein-3, MCP-3) and CCL3 (macrophage inflammatory 
protein-1alpha, MIP-1alpha) selectively attract monocytes/macrophages, eosinophils, 
basophils, and T lymphocyte [93]. Chemokine receptors belong to the large family of 
seven transmembrane domain receptors which couple to heterotrimeric G-coupled 
receptor proteins [94,95]. CXCL10 was initially identified from human 
IFN-gamma-inducible protein of 10 kDa (IP-10) as an early response gene induced by 
IFN-gamma in monocytes-like U937 cells line [96]. Early studies dominantly 
identified the enlargement of the pathogenic role of CXCL10 and its so far sole known 
receptor CXCR3 in diverse immune system disorders involving the trafficking of 
inflammatory immune cells, on T cells, NK cells, dendritic cells (the majority of which 
were T cells), which potentiated CXCL10-CXCR3 for a long time to be an essential 
putative therapeutic target due to their pathogenesis development [97-101]. 
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A broad set of investigations manifested that CXCL10 expression can be strongly 
induced in a variety of cell types e.g. endothelial cells, keratinocytes, fibroblasts, 
mesangial cells, astrocytes, monocytes, and neutrophils by stimulation with IFN-alpha, 
IFN-beta, IFN-gamma or lipopolysaccharide (LPS) [102-104]. Administration of 
exogenous IFN-gamma reversed the repression of CXCL10 on recruited exudative 
macrophages in CXCR3-silent rats and reflected again the causal connection between 
IFN-gamma and CXCL10, and the neutralization of virus-induced IFN-alpha/beta 
resulted in the downregulation of CXCL10 expression. IFN-alpha or IFN-gamma was 
found to directly promoted CXCL10 mRNA expression [105,106]. On the other hand, 
accumulating evidence supports the possibility that a positive feedback loop exists 
between IFN-gamma, CXCL10 and CXCR3, e.g. IFN-gamma levels as well as the 
number of CXCR3+CD4+ T cells were markedly reduced in both the lung and 
peripheral lymph node following CXCL10 neutralization [107]. CXCR3-null mice also 
in return impaired the production of IFN-gamma and CXCL10 [108]. These evidences 
supported that CXCL10 is an alternative marker of IFN-gamma in clinical diagnosis 
[109]. 
 
In line with previous investigations we observed a consistent upregulation of CXCR3 
on macrophages (Fig. 18) as well as CXCL10 in the inflamed paw (Fig. 16) by EA, 
providing potential receptor availability for its ligand CXCL10, although the 
quantification level of CXCR3 and exact role in CXCL10 mediated antinociception 
might still need to be evaluated and understood. Additionally the distinctive 
upregulation of IFN-gamma (Fig. 15F) concomitant with CXCL10 (Fig. 16) by EA 
among the targeted cytokines validly confirmed the causal correlation between them, 
which was illustrated by earlier researchers, and implied another alternative target for 
investigating the signaling pathway of CXCL10 in EA. 
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4.4 Bilateral role of chemokines in regulating pain and novel 
antinociceptive property of CXCL10 in relieving 
inflammatory pain by EA 
So far known cytokines and chemokines played a bilateral role in mediating both 
hyperalgesic and anti-hyperalgesic effects in inflammatory pain, e.g. as previously 
illustrated hyperalgesia-inducing mediators [32,33], TNF-alpha and IL-1beta 
themselves were also able to evoke considerable antinociception, which could be 
abolished by opioid antagonists [25,28]. Chemokine CXCL2/3 plays an important role 
in neutrophils recruitment and opioid release in the local inflammatory 
microenvironment [27]. Another chemokine CCL2 as well as its receptor 
C-C-chemokine receptor type 2 (CCR2) on monocytes/macrophages were considered 
as the key mediators for inducing inflammatory hyperalgesia as well as chronic pain 
[46,110]. 
 
Similarly, despite the promotion in pathogenesis development, increasing 
investigations also indicated that CXCL10 and CXCR3 exhibited an advantageous 
property in specific immune responses. It was manifested that systemic levels of 
CXCL10 are beneficial in controlling the allergic response, possibly by regulating 
cellular trafficking in the lymph node, whereas local administration of exogenous 
CXCL10 during an allergic response may be detrimental [111]. CXCR3 (-/-) mice had 
more severe chronic disease with increased demyelination and axonal damage [112]. 
CXCL10 (-/-) mice showed decreased luminal plaque, increased aortic size, worse 
morphological grades of aneurysms as well as a higher incidence of death due to aortic 
rupture, indicating a protective role against aneurysm formation and rupture in 
atherosclerotic plaque development [113]. In other words, the role of CXCL10 in the 
immune response has not been clearly understood. The currently conflicting results 
among diverse inflammatory models imply the complex and multiple roles of CXCL10 
and CXCR3 in the specific inflammatory or autoimmune diseases [114], which might 
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be dependent on different stages and perspectives of immune response in different 
models. In the current study, we found application (i.pl.) of the anti-CXCL10 Ab could 
time- and dose-dependently inhibited EA elicited antinociception at 96 h CFA (Fig. 
23A) and repeated administration (i.pl.) of anti-CXCL10 Ab could greatly abolish the 
daily pain threshold baseline of EA (Fig. 23B) and largely suppress opioid peptide 
expression (Fig. 24), indicating a direct correlation between CXCL10 and opioid 
peptides-expressing monocytes/macrophages. 
 
In the meantime, the majority researchers agree that CXCL10-CXCR3 mediated T cell 
trafficking, the expression and regulation of CXCL10 and CXCR3 by macrophages, 
was for a long time poorly put forward. In the present study, we firstly confirmed the 
early theory for the predominately analgesic role of monocytes/macrophages in 
contributing to opioid peptide release at 96 h CFA by observing the dominant 
expression of monocytes/macrophages as opposed to T cells (Fig. 17), which was in 
line with earlier report [45]. Addionally, the majority of macrophages expressed 
CXCR3 (Fig. 18) as well as upregulation of CXCL10 (Fig. 16) consistently backed up 
the possibility of the CXCL10-CXCR3 axis in modulating macrophages trafficking and 
opioid peptides expression. 
 
During inflammation, large amount of pro-inflammatory and pro-algesic mediators 
were secreted by immune cells trafficked to the inflammatory site, which sensitized 
nociceptor on nerve terminals and induced pain [115]. Immune cells e.g. neutrophils 
could also continuously release considerable amounts of opioid peptides to attenuate 
pain, triggering by calcium influx via activated PI3K due to mycobacterial components 
formyl peptides binding to FPR [29]. In recent studies, a hyperalgesic role of 
chemokine-receptor axis CCL2-CCR2 was suggested to be necessary for 
monocytes/macrophages-evoked hyperalgesia in CFA inflammation [46]. The 
hyperalgesic property of specific chemokines in neuropathic and other pain models was 
addressed by other researchers [110,116,117]. Nevertheless, from a controversial angle, 
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in earlier publications we also indicated that the chemokine-receptor alliance CXCL2/3 
and CXCR1/2 alleviated inflammatory pain through chemotaxis to neutrophils, 
whereby opioid peptides were released depending on intracellular calcium mobilization 
as well as PI3K cascade [27]. Notably, local injection of CXCL1 or CXCL2/3 in 
non-inflamed tissue could only recruit neutrophils without inducing hyperalgesia [118]. 
This increasing evidence facilitated the novel concept that chemokines and their 
receptors processed bi-directional natures in mediating the inflammatory response, as 
announced by earlier researchers [119,120]. 
 
Inflammatory rat peritoneal macrophages have been commonly used as differentiated 
monocytic cells in our previous in vitro investigations [46]. In this study, CXCL10 did 
not stimulate END secretion from inflammatory peritoneal rat macrophages (Fig. 22) 
in vitro even though the content of opioid expressing-monocytes/macrophages were 
intensively increased by repeated treatments of CXCL10 (Fig. 21), which was not in 
complete line with the opioid peptide-dependent anti-hyperalgesia of CXCL10 in vivo 
(Fig. 20). However, CXC-chemokines in earlier studies played an dual role in 
neutrophils migration and opioid peptide release (END and ENK) at an early period of 
CFA (2 h) [27]. Additionally this secretion of opioid peptide from CXC-chemokine 
was dose-dependent and intracellular Ca2+ level determined [27]. Notably, we 
previously experienced mycobacterial component Mycobacterium butyricum 
stimulation on neutrophils but not monocytes could directly trigger opioid peptide 
(END and ENK) release [29]. Similarly, our new study [121] explored subtypes of 
macrophages and discovered that neither pro-inflammatory M1 macrophages nor 
anti-inflammatory M2 macrophages favored the secretion of opioid peptide except 
exposing to ionomycin or toll like receptor (TLR) 2/4 ligand LPS, although the robust 
expression of TLR 4 on both subpopulations of macrophages was observed. Tracing 
back all the documents, unlike neutrophils, monocytes/macrophages are a group of 
cell-type dull to extra stimuli. Therefore, finding out potential molecular targets for 
macrophages activation would be pivotal to illustrate the subcellular pathway of 
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CXC-chemokine mediated opioid peptide secretion from macrophages, and optimal 
stimulation duration and mode as well as the dose of CXCL10 would also needed to 
be well established in vitro in further studies. 
 
The majority of references emphasized the critical role of CXCL10 in cell infiltration 
which tempted the secretion of pro-inflammatory cytokine from immune cells, 
however in the presented data, the upregulation of CXCL10 was not accompanied with 
the upregulation, but selective downregulation of hyperalgesic pro-inflammatory 
cytokine TNF-alpha and IL-1beta, indicating the co-existence of analgesic and 
anti-inflammatory properties by EA. These data constitutively support the specific 
advantages of CXCL10 by EA, which might be involved in independent specific 
cellular pathways in interacting with peripheral opioid peptide-containing immune 
cells. It is also predictable that, at least in a given phase (96 h) of peripheral 
inflammatory pain, CXCL10 is presented to be the key analgesic mediator, thus 
neutralization of CXCL10 as a therapeutic approach at this phase would undoubtedly 
impair the predominantly beneficial effects as opposed to increasing the possibly 
detrimental effects. 
 
In summary, this thesis extends the current understanding on electroacupuncture 
induced analgesia at a late stage (96 h) of CFA induced inflammation and puts forward 
new information, predominantly with chemokine CXCL10 mediated EA produced 
tonic antinociception via peripheral opioid peptides and modulated the expression of 
opioid peptide on monocytes/macrophages. Partial restoration of certain local 
cytokines expression by EA may be relevant to both anti-inflammation and 
anti-hyperalgesia properties of EA. Intensified upregulation of CXCL10 as well as 
CXCR3 expression on macrophages at inflammation site might be associated with the 
antinociceptive property of CXCL10 in EA and need to be clarified further. 
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Laying a solid foundation on the 3D modeled acupoint position and acupuncture 
needling approach in this thesis, the results point towards elucidation of the possible 
signaling pathways involved in both opioid and non-opioid mechanisms. Future 
intensive, rigorous and quantitative acupuncture research needs to be directed towards 
determining the correlation between cytokines/chemokines and acupuncture induced 
analgesia. 
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Appendix 
Units 
°C 
cm 
g 
h 
M 
g
l 
m 
mA 
min 
mg 
ml 
mm 
mM 
ng 
nm 
pg 
rpm 
s 
V 
degrees Celsius 
centimeter 
gram 
hour 
molar 
microgram 
microliter 
micrometer 
milliampere 
minute 
milligram 
milliliter 
millimetre 
millimolar 
nanogram 
nanometer 
picogram 
rotations per minute 
second 
volt 
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